Kidney Sarcoma

MONDO:0002930 Pathograph 7 Show in embeddings browser kidney cancer sarcoma

Kidney sarcoma is a rare group of primary malignant mesenchymal neoplasms of the kidney, accounting for roughly 1-3% of adult renal malignancy. Unlike the renal cell carcinomas, which arise from tubular epithelium, these tumours arise from the non-epithelial compartments of the organ - the smooth muscle of the intrarenal vessels and renal pelvic wall, the renal capsule and perinephric connective tissue, the sinus fat, and the vascular endothelium. That mesenchymal origin is the entry's organising claim, and everything downstream of it follows: no epithelial differentiation means none of the VEGF- and mTOR-directed systemic framework built for renal cell carcinoma applies, and the tumours are correspondingly resistant to radiotherapy and conventional chemotherapy, leaving complete surgical resection as the only treatment that reliably changes outcome. Growing in the retroperitoneum, they distend rather than obstruct and so reach a large size before producing the non-specific triad of flank pain, haematuria and a palpable mass; renal vein and inferior vena cava invasion with early haematogenous dissemination is characteristic, and survival is markedly worse than for renal cell carcinoma of comparable stage. The category is broad: the largest registry series counts 43 histiotypes under the renal-sarcoma heading. This entry models the six that account for most reported disease - leiomyosarcoma (the commonest), liposarcoma, angiosarcoma (the most lethal), synovial sarcoma, rhabdomyosarcoma, and Ewing sarcoma - as `has_subtypes`, rather than as a `kb/groupings/` union. See `curation_scope_rationale` in the notes on the first pathophysiology node for why; briefly, the members share a genuine anatomic-and-clinical pathograph but not a driver, and the pan-site histology entries already in the knowledge base (Leiomyosarcoma, Liposarcoma, Angiosarcoma, Synovial_Sarcoma) are not scoped to the kidney, so a Grouping over them would mis-state their extent. Explicitly excluded: sarcomatoid renal cell carcinoma (an epithelial carcinoma with mesenchymal-appearing dedifferentiation, which is the principal differential and must be excluded by keratin/epithelial-marker immunohistochemistry before a primary renal sarcoma is diagnosed), Wilms tumour/nephroblastoma, and the paediatric renal tumours clear cell sarcoma of the kidney and rhabdoid tumour of the kidney, which have their own entries.

Ask OpenScientist

Ask a research question about Kidney Sarcoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

6
Pathophys.
4
Histopath.
5
Phenotypes
4
Gaps
7
Pathograph
9
Genes
3
Medical Actions
6
Subtypes
1
Datasets
1
Deep Research
🏷

Classifications

ICD-O Morphology
Sarcoma
Harrison's Part
ONCOLOGY HEMATOLOGY
◆

Subtypes

6
Renal Leiomyosarcoma NCIT:C6183
The commonest primary renal sarcoma, arising from the smooth muscle of the intrarenal blood vessels, the renal capsule, or the renal pelvic wall. Mean age at presentation is 50-60 years with a female preponderance. Genomically complex rather than fusion-driven, with recurrent loss of TP53, RB1 and ATRX pathway function; high rate of local recurrence and haematogenous metastasis.
Show evidence (1 reference)
PMID:32491531 SUPPORT Human Clinical
"Renal leiomyosarcoma (LMS) is a rare and aggressive mesenchymal tumor that usually arises from the smooth muscle cells of the intrarenal blood vessels or the renal pelvis."
Establishes the cell of origin and mesenchymal character of the commonest renal sarcoma subtype.
Renal Liposarcoma NCIT:C6185
Adipocytic sarcoma arising from the fat of the renal sinus, capsule or perinephric tissue. Its principal diagnostic difficulty is radiological: a fat-containing renal mass is far more often a benign angiomyolipoma, and well-differentiated renal liposarcoma can be indistinguishable on imaging alone. Well-differentiated and dedifferentiated forms carry the 12q13-15 amplicon containing MDM2 and CDK4, which is the diagnostic discriminator from benign lipomatous lesions.
Show evidence (1 reference)
PMID:38312755 SUPPORT Human Clinical
"In extremely rare instances, the tumor can arise directly from the fat in the epicenter of the kidney, disguised as an angiomyolipoma."
Supports both the adipocytic renal origin of this subtype and the angiomyolipoma mimicry that makes it a diagnostic problem.
Renal Angiosarcoma NCIT:C159205
Endothelial-derived sarcoma of the renal vasculature. The rarest of the common subtypes and by a wide margin the most lethal - in the Japanese national registry it carried a hazard ratio for death of 12.65 and a 3-year survival of 19.0%. Frequently presents with spontaneous haemorrhage into or around the tumour, and with direct extension into the renal vein and perirenal fat.
Show evidence (1 reference)
PMID:41777120 SUPPORT Human Clinical
"histologic subtype (angiosarcoma: HR, 12.65; p < 0.001), and distant disease (HR, 6.32; p < 0.001) were significant independent prognostic factors"
Quantifies angiosarcoma histology as an independent adverse prognostic factor within renal sarcoma.
Renal Synovial Sarcoma NCIT:C157737
A translocation-driven sarcoma defined by the SS18::SSX1/2 fusion, accounting for under 1% of renal sarcomas. Unlike the other subtypes it has a single defining genetic lesion, detectable by SS18-SSX immunohistochemistry as a surrogate for FISH. Spindle-cell, round-cell and epithelioid morphologies all occur, and the round-cell pattern is a recognised mimic of other small round-blue-cell renal tumours.
Show evidence (1 reference)
PMID:36591871 SUPPORT Human Clinical
"Primary renal synovial sarcoma is a rare aggressive mesenchymal neoplasm of the kidney that accounts for less than 1% of renal sarcomas."
Establishes renal synovial sarcoma as a distinct, rare mesenchymal subtype within renal sarcoma.
Renal Rhabdomyosarcoma NCIT:C159206
Skeletal-muscle-differentiated sarcoma of the kidney, extremely rare in adults, where it behaves far more aggressively than the paediatric disease. Most reported adult cases are embryonal. Because rhabdomyoblastic differentiation is not a normal constituent of the kidney, this subtype is considered to arise from primitive mesenchyme with divergent myogenic differentiation rather than from a resident myocyte population.
Show evidence (1 reference)
PMID:37753457 SUPPORT Human Clinical
"Primary embryonal rhabdomyosarcomas of the kidney are extremely rare, especially in adults."
Supports the rarity of this subtype and its predominantly embryonal histology in adults.
Renal Ewing Sarcoma / Primitive Neuroectodermal Tumour NCIT:C159208
A small round blue cell sarcoma of the Ewing family arising primarily in the kidney, driven by an EWSR1::FLI1 or related ETS-family fusion. It is the one subtype for which there is direct evidence that the renal site changes behaviour rather than merely relocating a familiar tumour: in a pooled analysis of 362 reported cases, metastases were present at diagnosis in 53% of renal Ewing sarcoma against 20-25% for the Ewing family overall, and nodal disease in 24% against 3.2% for primary skeletal Ewing sarcoma. It presents at a much younger age than the other renal sarcomas - adolescents and young adults rather than the sixth decade - and is treated on Ewing-family multimodal protocols rather than as a renal tumour.
Show evidence (1 reference)
PMID:32282650 SUPPORT Human Clinical
"Notably, while the general ESFT population has reported rates of metastasis at diagnosis of 20% to 25%, this rate in the renal ESFT population was 53% with a rate of 59% in adolescent and young-adult patients (11 to 24 y)."
Quantifies the excess metastatic burden at diagnosis specific to the renal site, the observation on which this subtype's description rests.
?

Discussions and Knowledge Gaps

4
Is radiotherapy genuinely active in primary renal sarcoma, or is the registry survival association an artefact of selecting fitter patients with resectable disease?
KNOWLEDGE GAP renal_sarcoma_radiotherapy_discordance
Attached to
treatments#Radiation Therapy
The literature consistently describes renal sarcoma as radioresistant, yet the Japanese national registry found radiation therapy independently associated with improved survival (HR 0.39, p = 0.010) on multivariable analysis. Registry analyses cannot adjust for performance status, resection completeness, or the clinical reasoning that led to radiotherapy being offered, so the two observations are not necessarily in conflict - but the discordance is unresolved and matters, because it is the difference between a treatment with no role and one that is being under-used in a disease with almost no systemic options.
Does arising in the kidney change the biology of a given sarcoma histology, or is renal site purely an anatomical accident with no molecular correlate?
KNOWLEDGE GAP renal_site_molecular_correlate
Attached to
pathophysiology#Subtype-Specific Driver Lesion Acquisition
Everything modeled in this entry as shared across subtypes is anatomical and clinical - retroperitoneal silent growth, renal venous invasion, absence of an epithelial therapeutic target - and nothing is established as shared at the molecular level. There is one partial answer, and it points toward the site mattering: renal Ewing sarcoma is metastatic at diagnosis in 53% of pooled reported cases against 20-25% for the Ewing family overall, and has nodal disease in 24% against 3.2% for skeletal primaries, despite carrying the same defining fusion. Whether that reflects a genuine microenvironmental effect, the vascular anatomy of the kidney, or simply later detection in a silent compartment is unresolved - and the equivalent comparison has never been made for the commoner subtypes. No study has compared the genomes of renal leiomyosarcoma or renal angiosarcoma with their much commoner counterparts at other sites. If the site has no molecular correlate, the case for a site-based entry rests entirely on the clinical pathograph; if it does, the shared node set should grow. This is the empirical question underlying the lump-versus-split decision recorded on the first pathophysiology node.
Does managing primary renal sarcoma under renal cancer guidelines rather than soft-tissue sarcoma guidelines cost survival, and by how much?
KNOWLEDGE GAP renal_vs_sts_guideline_mismatch
Attached to
pathophysiology#Absence of Epithelial Therapeutic Target treatments#Adjuvant Chemotherapy
The largest registry series found that renal sarcomas behave as soft-tissue sarcomas but are treated according to renal cancer guidelines. If the two frameworks agreed on management the observation would be of no consequence, but they do not: soft-tissue sarcoma practice routes patients to a sarcoma reference centre, selects the cytotoxic regimen by histiotype, and considers neoadjuvant therapy for large high-grade tumours, none of which follows from a renal cancer pathway. No study has compared outcomes between patients managed under the two frameworks, and because the disease is too rare for a randomised trial the answer would have to come from a registry analysis stratified by whether care was delivered at a sarcoma centre. Until then the size of the gap between how these tumours behave and how they are treated is unmeasured.
Is there any public molecular dataset of primary renal sarcoma, and if not, what is the smallest cohort that would settle whether the renal site has a molecular signature?
KNOWLEDGE GAP no_renal_sarcoma_molecular_dataset
Attached to
datasets# pathophysiology#Subtype-Specific Driver Lesion Acquisition
This entry carries one `datasets:` record, and what is missing around it is the finding. A GEO sweep for renal sarcoma and its named subtypes returns exactly one series profiling a tumour this entry covers - a single BCOR-CCNB3 undifferentiated sarcoma of the kidney. Everything else that scores highly on name match profiles clear cell sarcoma of the kidney or rhabdoid tumour of the kidney, both explicitly excluded here, and the remainder mention the search terms only incidentally. There is no molecular dataset at all for renal leiomyosarcoma, the commonest histiotype, nor for renal angiosarcoma, the most lethal. At an incidence of 0.53 cases per million person-years spread across 43 histiotypes, no single institution accumulates enough tissue to profile, so the gap is structural rather than accidental. It is also the reason the site-versus-molecular-correlate question above cannot currently be answered: the comparison needs renal and non-renal cases of the same histiotype sequenced together, and that cohort would have to be assembled prospectively across a sarcoma consortium. Any accession added here in future must be checked for relevance rather than accepted because it resolves; searching a causal gene or relaxing the disease name in this space returns Wilms tumour, clear cell sarcoma of the kidney and sarcomatoid renal cell carcinoma, none of which is this disease.
⚙

Pathophysiology

6
Malignant Transformation of Renal Mesenchyme
Kidney sarcomas arise by malignant transformation of the non-epithelial compartments of the kidney - the smooth muscle of the intrarenal arteries, veins and renal pelvic wall; the fibrous capsule and perinephric connective tissue; the adipose tissue of the renal sinus; and the vascular endothelium. This is the definitional node of the entry and the point at which it diverges from every renal cell carcinoma: there is no tubular epithelial precursor and no epithelial differentiation programme, so the transformed cell retains a mesenchymal phenotype from the outset. Which mesenchymal lineage transforms determines the histological subtype, and the transforming lesions differ completely between lineages - complex chromosomal loss in leiomyosarcoma and angiosarcoma, the 12q13-15 MDM2/CDK4 amplicon in liposarcoma, and the single SS18::SSX fusion in synovial sarcoma.
mesenchymal stem cell CL:0000134 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves mesenchymal stem cell (CL:0000134). CL:0000134 is a cell type from the Cell Ontology. vascular smooth muscle cell of the intrarenal vessels CL:0000192 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves vascular smooth muscle cell of the intrarenal vessels, annotated with smooth muscle cell (CL:0000192). CL:0000192 is a cell type from the Cell Ontology. renal vascular endothelial cell CL:0002139 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves renal vascular endothelial cell, annotated with endothelial cell of vascular tree (CL:0002139). CL:0002139 is a cell type from the Cell Ontology. renal sinus adipocyte CL:0000136 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves renal sinus adipocyte, annotated with adipocyte (CL:0000136). CL:0000136 is a cell type from the Cell Ontology.
cell population proliferation GO:0008283 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cell population proliferation (GO:0008283). GO:0008283 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Subtype-Specific Driver Lesion Acquisition The transformed mesenchymal lineage determines which driver lesion class is acquired and therefore which histological subtype results.
Diagnostic Confusion with Sarcomatoid Renal Cell Carcinoma The absence of an epithelial differentiation programme is precisely what a dedifferentiated renal cell carcinoma mimics morphologically, so mesenchymal origin is what has to be demonstrated at diagnosis rather than assumed.
Show evidence (1 reference)
PMID:32491531 SUPPORT Human Clinical
"Renal leiomyosarcoma (LMS) is a rare and aggressive mesenchymal tumor that usually arises from the smooth muscle cells of the intrarenal blood vessels or the renal pelvis."
Names the mesenchymal compartments of the kidney - intrarenal vascular smooth muscle and renal pelvis - as the site of origin, which is the claim this node makes.
Subtype-Specific Driver Lesion Acquisition
The genetic route to malignancy is not shared across the subtypes, and this node exists to say so explicitly rather than to assert a common driver. Two genetic architectures are represented. The majority of renal sarcomas - leiomyosarcoma, angiosarcoma and dedifferentiated liposarcoma - are genomically complex: they carry aneuploid, structurally rearranged genomes produced by loss of tumour-suppressor and genome-maintenance function (TP53, RB1, ATRX) rather than by a single positive driver, which is the chromosomal instability arm of the genome-instability hallmark. A minority - renal synovial sarcoma - is instead fusion-driven, defined by a single SS18::SSX1/2 translocation on a near-diploid background, and does not conform to the mutator phenotype at all. Well-differentiated liposarcoma sits between the two with a focal, recurrent amplicon (12q13-15, containing MDM2 and CDK4). This heterogeneity is not an annotation artefact: national registry data show histological subtype to be the single strongest predictor of survival within renal sarcoma, with 3-year survival ranging from 19.0% for angiosarcoma to 94.4% for clear cell sarcoma of the kidney, and the largest combined SEER/NCDB series counts 43 distinct histiotypes under the renal-sarcoma heading with differing sensitivity to systemic therapy. The practical corollary, and the reason this node is modeled as divergence rather than as a shared driver, is that treatment selection follows the histology and not the organ.
DNA repair GO:0006281 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased DNA repair (GO:0006281). GO:0006281 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Silent Retroperitoneal Expansion Unchecked proliferation of the transformed mesenchymal clone produces the expanding retroperitoneal mass.
Show evidence (3 references)
PMID:41777120 SUPPORT Human Clinical
"Histologic subtype is the most critical prognostic factor for renal sarcoma in Japan's aging population, with dramatic survival differences: clear cell sarcoma (94.4% 3-year survival) versus angiosarcoma (19.0%)."
Directly supports the claim that the subtypes are biologically distinct rather than variants of one process, quantified as a survival difference of 75 percentage points at 3 years.
PMID:38693188 SUPPORT Human Clinical
"renal sarcomas include 43 histiotypes with distinct epidemiology, clinical presentation, outcomes and sensitivity to systemic therapy, thereby reflecting soft-tissue sarcoma behavior"
The largest combined SEER/NCDB series states the driver and behavioural heterogeneity this node models, and locates renal sarcoma's behaviour with soft-tissue sarcoma rather than with renal cancer.
PMID:36591871 SUPPORT Human Clinical
"All the tumors harbored SS18::SSX1/2 gene rearrangement."
Supports the fusion-driven arm of this node - renal synovial sarcoma is uniformly defined by a single translocation - and so supports the claim that driver architecture differs between subtypes. PARTIAL because it speaks only to the synovial subtype, not to the complex-karyotype majority.
Silent Retroperitoneal Expansion
The kidney sits in a distensible retroperitoneal compartment, and a mesenchymal tumour growing within the renal capsule, sinus or perinephric tissue displaces structures rather than obstructing them. There is no early symptom analogous to the obstructive or bleeding presentation of tumours in a lumen, so the tumour is typically large at diagnosis - reported primary renal sarcomas are commonly 6-12 cm or greater - and produces only the non-specific triad of flank pain, haematuria (when the mass reaches the collecting system) and a palpable mass. This delay is the mechanism by which stage at diagnosis, itself the dominant prognostic variable, is set: in the SEER cohort stage III disease carried a hazard ratio for death of 4.93 against stage I, and median survival fell from 105 months to 8 months.
Downstream
Vascular Invasion and Haematogenous Dissemination Continued local growth brings the tumour into contact with, and then through, the renal venous system.
Show evidence (3 references)
PMID:36045013 SUPPORT Human Clinical
"Median survival was 105 months (interquartile range [IQR], 29 - not reached) for stage I disease, 46 months (IQR 14-118 months) for stage II disease, 8 months (IQR 3-28 months) for stage III disease"
Quantifies the consequence of the delayed presentation modeled here: stage at diagnosis separates median survival by more than an order of magnitude.
PMID:34102790 SUPPORT Human Clinical
"CT scan revealed an enhancing, heterogeneous, 6×7×9 cm right renal mass."
A representative incidentally detected renal leiomyosarcoma already 9 cm at diagnosis, illustrating the large size reached before detection. PARTIAL because a single case documents the pattern without establishing its frequency.
PMID:38693188 SUPPORT Human Clinical
"Patients presented with advanced local extent (T3 33.3%; T4 14.2%) or distant metastases (29.1%) and commonly underwent surgical resection (81.6%)."
Quantifies the late presentation this node models at population scale: nearly half of adult renal sarcomas are T3 or T4 and almost a third are already metastatic when first diagnosed.
Vascular Invasion and Haematogenous Dissemination
Renal sarcomas invade locally through the perirenal fat and into the renal vein, and from there into the inferior vena cava, occasionally as a tumour thrombus reaching the right atrium. Because the subtypes originate in or adjacent to the renal vasculature, intravasation is anatomically immediate rather than a late acquired capability, and dissemination is predominantly haematogenous rather than lymphatic - the liver, lung, bone and brain are the usual destinations. Note that the epithelial-mesenchymal transition step of the invasion-and-metastasis module is deliberately not claimed here: these cells are mesenchymal from the outset and never undergo a phenotype switch to acquire motility.
cell migration GO:0016477 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cell migration (GO:0016477). GO:0016477 is a biological process from the Gene Ontology. ↑ INCREASED extracellular matrix organization GO:0030198 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased extracellular matrix organization (GO:0030198). GO:0030198 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Absence of Epithelial Therapeutic Target Once disease is disseminated, treatment depends on systemic options, and the mesenchymal phenotype determines that none of the renal-cell-carcinoma options apply.
Show evidence (3 references)
PMID:32491531 SUPPORT Human Clinical
"Renal LMS frequently metastasizes to distant body organs via hematogenous spread and carries an overall poor prognosis."
Directly supports haematogenous rather than lymphatic dissemination as the dominant metastatic route.
PMID:30061122 SUPPORT Human Clinical
"Final pathology was pT2b with extension of the mass into the renal vein and perirenal adipose tissue."
Documents the renal vein and perirenal fat invasion that this node models, in the angiosarcoma subtype.
PMID:42050503 SUPPORT Human Clinical
"A 49-year-old man was admitted with a left kidney mass and inferior vena cava (IVC) tumor thrombus extending into the right atrium (Mayo grade IV)."
Documents the extreme of the venous-invasion phenotype modeled here - a tumour thrombus propagating from the renal vein through the vena cava to the right atrium.
Absence of Epithelial Therapeutic Target
The therapeutic consequence of the mesenchymal origin. The entire modern systemic framework for kidney cancer - VEGF-pathway tyrosine kinase inhibition, mTOR inhibition, and PD-1/CTLA-4 checkpoint blockade - was built on clear cell renal cell carcinoma biology (VHL loss, hypoxia-inducible factor stabilisation, a high-neoantigen immunogenic epithelial tumour) and none of it has a target in a renal sarcoma. Conventional soft-tissue sarcoma chemotherapy and radiotherapy are correspondingly of limited benefit, so complete surgical excision with negative margins is the only intervention that reliably alters outcome, and local recurrence after incomplete resection is common. This node is the mechanistic reason that kidney sarcoma carries a worse prognosis than renal cell carcinoma of equivalent stage, and it is why distinguishing the two at diagnosis matters clinically rather than only taxonomically.
Show evidence (3 references)
PMID:42050503 SUPPORT Human Clinical
"They progress rapidly and are resistant to radiotherapy and chemotherapy. Currently, surgery is the only effective treatment."
Directly supports the therapeutic corollary of this node - resistance to both radiotherapy and chemotherapy, leaving surgery as the only effective treatment.
PMID:32491531 SUPPORT Human Clinical
"There is a high tendency for local recurrence; hence, complete surgical excision is recommended."
Supports complete surgical excision as the management principle and local recurrence as the failure mode when it is not achieved.
PMID:38693188 SUPPORT Human Clinical
"Renal sarcoma treatment patterns follow recommendations by renal cancer guidelines with surgical resection as the cornerstone of therapy."
Confirms surgical resection as the cornerstone of therapy, and documents that practice is guided by renal cancer guidelines even though the tumours behave as soft-tissue sarcomas - the mismatch this node explains.
Diagnostic Confusion with Sarcomatoid Renal Cell Carcinoma
A distinct pathological node rather than a clinical aside, because the two entities converge morphologically from opposite directions. A renal sarcoma is a mesenchymal tumour that has always been mesenchymal; sarcomatoid renal cell carcinoma is an epithelial carcinoma that has undergone dedifferentiation to a spindle-cell morphology. On haematoxylin and eosin alone a high-grade spindle-cell renal mass is compatible with either, and the distinction rests on demonstrating epithelial differentiation - cytokeratin and EMA expression, or a recognisable carcinomatous component - which is present in sarcomatoid renal cell carcinoma and absent in a true sarcoma. The distinction is not academic: sarcomatoid renal cell carcinoma remains a carcinoma for therapeutic purposes and retains access to checkpoint-inhibitor combinations, whereas a renal sarcoma does not. Sarcomatoid renal cell carcinoma is also far commoner, so it is the default diagnosis a spindle-cell renal mass must be argued out of.
Downstream
Absence of Epithelial Therapeutic Target Resolving the differential in favour of a true sarcoma is what commits the patient to the therapeutic dead end below - a sarcomatoid renal cell carcinoma remains a carcinoma and keeps access to checkpoint-inhibitor combinations, a renal sarcoma does not.
Show evidence (2 references)
PMID:32491531 SUPPORT Human Clinical
"Since the prognosis for a renal sarcoma is particularly poor, differentiation from sarcomatoid renal cell carcinoma is necessary."
States the differential-diagnostic requirement this node models and the prognostic reason it matters.
PMID:26902877 SUPPORT Human Clinical
"sRCC was associated with a 3.2 higher risk of CSM compared with ccRCC"
Characterises the entity a renal sarcoma must be distinguished from - sarcomatoid renal cell carcinoma is itself an aggressive epithelial tumour, which is why morphology alone cannot separate them on clinical grounds. PARTIAL because the paper compares sarcomatoid to clear cell renal cell carcinoma and does not address primary renal sarcoma.
✶

Histopathology

4
Tumor Necrosis
Coagulative tumour necrosis is common in these large, rapidly growing masses that outstrip their blood supply, and it is one of the independent predictors of shorter overall survival in the largest registry series. It is also the structural substrate of the spontaneous haemorrhage seen in the angiosarcoma subtype.
Show evidence (1 reference)
PMID:38693188 SUPPORT Human Clinical
"Longer OS was independently associated with younger age, female sex, lower comorbidity index, low T stage, negative surgical margins, absence of tumor necrosis or distant metastases and leiomyosarcoma histiotype"
Names absence of tumour necrosis as an independent predictor of longer survival, so its presence is an adverse histopathological finding.
Pleomorphic Spindle Cell Morphology
Dedifferentiated renal liposarcoma is a non-lipogenic pleomorphic spindle cell tumour in a vascular and collagenous stroma. On morphology alone it is not separable from other pleomorphic sarcomas, which is why the MDM2/CDK4 tests carry the diagnosis rather than the histology.
Show evidence (1 reference)
PMID:38693188 SUPPORT Human Clinical
"Core needle biopsy tissue demonstrating dedifferentiated liposarcoma with pleomorphic spindle cells within a vascular and collagenous stroma."
Describes the morphology of renal dedifferentiated liposarcoma on core needle biopsy.
Small Round Blue Cell Morphology
Vaguely lobular sheets of small round blue cells with hyperchromatic nuclei and pseudo-rosette formation. This pattern overlaps with the round-cell variant of renal synovial sarcoma and with the paediatric renal tumours this entry excludes, which is why fusion confirmation is required rather than optional.
Show evidence (1 reference)
PMID:38693188 SUPPORT Human Clinical
"Core needle biopsy tissue demonstrating renal PNET with vaguely lobular growth of small round blue cells with hyperchromatic nuclei and pseudo-rossette formation"
Describes the small round blue cell morphology of the renal Ewing/PNET primary on core needle biopsy.
Atypical Endothelial-Lined Vascular Spaces
Vascular spaces lined by atypical endothelial cells, infiltrating and entrapping native renal cortex including glomeruli. The neoplastic cells form the vessels themselves, which is the structural reason this subtype bleeds.
Show evidence (1 reference)
PMID:38693188 SUPPORT Human Clinical
"Section from a 19 cm renal angiosarcoma involving the renal cortex with entrapped glomeruli. Inset: Higher magnification (400×) demonstrating vascular spaces lined by atypical endothelial cells."
Describes the infiltrative growth and atypical endothelial lining that define renal angiosarcoma histologically.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Kidney Sarcoma Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

5
Digestive 1
Palpable Abdominal Mass FREQUENT HP:0031500 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Palpable renal mass, annotated with Abdominal mass (HP:0031500). HP:0031500 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34102790 SUPPORT Human Clinical
"A 49-year woman was incidentally found to have a palpable mass in the right kidney."
Documents a palpable renal mass as the presenting finding in primary renal leiomyosarcoma.
Genitourinary 2
Hematuria OCCASIONAL HP:0000790 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hematuria (HP:0000790). HP:0000790 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32491531 SUPPORT Human Clinical
"Renal leiomyosarcoma (LMS) is a rare and aggressive mesenchymal tumor that usually arises from the smooth muscle cells of the intrarenal blood vessels or the renal pelvis."
Supports the anatomic premise for this phenotype - a subset of renal sarcomas arise in or reach the renal pelvis, which is the route to haematuria. PARTIAL because the cited passage establishes the anatomy, not the frequency of haematuria.
Renal Neoplasm VERY_FREQUENT HP:0009726 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Renal neoplasm (HP:0009726). HP:0009726 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:30061122 SUPPORT Human Clinical
"His pathology revealed a 12.5×6×4.5 cm mass consistent with angiosarcoma of the right kidney with negative margins."
Documents the renal mass that defines the presentation, at the large size characteristic of this disease.
Constitutional 1
Flank Pain FREQUENT HP:0030157 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Flank pain (HP:0030157). HP:0030157 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:30061122 SUPPORT Human Clinical
"presented to an outside hospital on 22 February 2017 with acute right flank pain"
Documents flank pain as the presenting symptom in a primary renal angiosarcoma.
Other 1
Tumor Hemorrhage Internal hemorrhage HP:0011029 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spontaneous perirenal/tumoral hemorrhage, annotated with Internal hemorrhage (HP:0011029). HP:0011029 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:30061122 SUPPORT Human Clinical
"He had a CT scan which revealed a large right renal mass with acute haemorrhage. He was initially managed with interventional radiology guided embolism on 25 February 2017 due to the ongoing bleeding and haemodynamic instability."
Documents spontaneous tumour haemorrhage causing haemodynamic instability and requiring embolisation in renal angiosarcoma.
🧬

Genetic Associations

9
SS18 (Somatic SS18::SSX1/2 translocation)
Gene: SS18 hgnc:11340 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SS18 (hgnc:11340). hgnc:11340 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER
Show evidence (1 reference)
PMID:36591871 SUPPORT Human Clinical
"SS18-SSX IHC was positive in all 14 tumors (diffuse, n = 10; multifocal, n = 2; focal, n = 2). All the tumors harbored SS18::SSX1/2 gene rearrangement."
Establishes the SS18::SSX1/2 rearrangement as universal in this cohort of renal synovial sarcoma and validates SS18-SSX immunohistochemistry as a surrogate.
SSX1 (Somatic fusion partner in SS18::SSX1 translocation)
Gene: SSX1 hgnc:11335 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SSX1 (hgnc:11335). hgnc:11335 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER
Show evidence (1 reference)
PMID:36591871 SUPPORT Human Clinical
"All the tumors harbored SS18::SSX1/2 gene rearrangement."
Names SSX1/2 as the fusion partner in every tumour of the renal synovial sarcoma cohort.
TP53 (Somatic loss-of-function mutation and deletion)
Gene: TP53 hgnc:11998 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TP53 (hgnc:11998). hgnc:11998 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER
Show evidence (1 reference)
PMID:29660202 SUPPORT Human Clinical
"whole-exome sequencing of u-LMS has confirmed and demonstrated frequent alterations in TP53, RB1, α-thalassemia/mental retardation syndrome X-linked (ATRX) and mediator complex subunit 12 (MED12)"
Establishes TP53, RB1 and ATRX as the recurrent alterations of leiomyosarcoma. PARTIAL, and deliberately so: the cohort is uterine leiomyosarcoma, not renal, so this supports the histology's driver class rather than a renal-specific finding. Graded HUMAN_CLINICAL because what the paper reports is human tumour genomics - TCGA and whole-exome sequencing of patient tumours - even though its format is a review.
RB1 (Somatic loss-of-function mutation and deletion)
Gene: RB1 hgnc:9884 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is RB1 (hgnc:9884). hgnc:9884 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER
Show evidence (1 reference)
PMID:29660202 SUPPORT Human Clinical
"In 2017, The Cancer Genome Atlas (TCGA) Research Network's work on u-LMS has confirmed mutations and deletions in RB1, TP53 and PTEN."
TCGA confirmation of RB1 mutation and deletion in leiomyosarcoma. PARTIAL because the cohort is uterine rather than renal. HUMAN_CLINICAL because TCGA is human tumour sequencing.
ATRX (Somatic loss-of-function mutation)
Gene: ATRX hgnc:886 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ATRX (hgnc:886). hgnc:886 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER
Show evidence (1 reference)
PMID:29660202 SUPPORT Human Clinical
"TP53 and ATRX mutations can be important mechanisms in the pathogenesis of u-LMS and are correlated with a poor prognosis."
Supports ATRX mutation as a pathogenic mechanism in leiomyosarcoma with prognostic weight. PARTIAL because the cohort is uterine rather than renal. HUMAN_CLINICAL because the underlying data are human tumour sequencing.
MDM2 (Somatic high-level 12q13-15 amplification)
Gene: MDM2 hgnc:6973 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is MDM2 (hgnc:6973). hgnc:6973 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER
Show evidence (1 reference)
PMID:30852045 SUPPORT Human Clinical
"both are associated with high-level amplifications in the chromosomal 12q13-15 region, which includes the CDK4 and MDM2 cell cycle oncogenes"
Establishes the MDM2/CDK4 amplicon as the shared genetic aberration of well-differentiated and dedifferentiated liposarcoma. PARTIAL because the review covers liposarcoma at all sites, predominantly retroperitoneal and extremity, rather than the renal primary. HUMAN_CLINICAL because the amplification data it summarises come from human tumour cytogenetics.
CDK4 (Somatic high-level 12q13-15 amplification)
Gene: CDK4 hgnc:1773 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CDK4 (hgnc:1773). hgnc:1773 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER
Show evidence (1 reference)
PMID:30852045 SUPPORT Human Clinical
"WDL and DDL share similar background genetic aberrations; both are associated with high-level amplifications in the chromosomal 12q13-15 region, which includes the CDK4 and MDM2 cell cycle oncogenes."
Names CDK4 within the defining 12q13-15 amplicon. PARTIAL because the review is not renal-specific. HUMAN_CLINICAL because the underlying amplification data come from human tumours.
EWSR1 (Somatic EWSR1::FLI1 (or related ETS-family) translocation)
Gene: EWSR1 hgnc:3508 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is EWSR1 (hgnc:3508). hgnc:3508 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER
Show evidence (1 reference)
PMID:32282650 SUPPORT Human Clinical
"While this malignant process may share histologic and molecular features with its bone and soft tissue counterparts, primary renal ESFT presentations seem to be more aggressive and have worse outcomes."
States that renal Ewing sarcoma shares the molecular features of the Ewing family - the EWSR1 rearrangement - while behaving more aggressively. PARTIAL because the quoted sentence asserts shared molecular features without naming the fusion partner.
FLI1 (Somatic fusion partner in EWSR1::FLI1 translocation)
Gene: FLI1 hgnc:3749 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is FLI1 (hgnc:3749). hgnc:3749 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER
Show evidence (1 reference)
PMID:32282650 SUPPORT Human Clinical
"The Ewing sarcoma family of tumors (ESFT) are high-grade small round blue cell malignancies traditionally presenting in children and adolescents."
Establishes the tumour family in which the EWSR1::FLI1 fusion is the defining lesion, and its age distribution. PARTIAL because the abstract does not itself name FLI1.
💊

Medical Actions

3
Radical Nephrectomy with Complete Surgical Excision
Action: Radical NephrectomyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Radical Nephrectomy (NCIT:C51778). NCIT:C51778 is a clinical intervention from the NCI Thesaurus. NCIT:C51778
The only intervention that reliably alters outcome. Radical nephrectomy with en-bloc resection of involved perinephric tissue and negative margins is the standard of care; where a renal vein or vena caval tumour thrombus is present, thrombectomy is performed with it, and a Mayo grade IV thrombus reaching the right atrium may require cardiopulmonary bypass with hypothermic circulatory arrest. Incomplete excision is followed by a high rate of local recurrence.
Mechanism Target:
Silent Retroperitoneal Expansion — Removes the primary mass and its retroperitoneal extensions before further local progression.
Show evidence (4 references)
PMID:42050503 SUPPORT Human Clinical
"They progress rapidly and are resistant to radiotherapy and chemotherapy. Currently, surgery is the only effective treatment."
States that surgery is the only effective treatment for primary renal sarcoma, which is the basis of this entry.
PMID:36045013 SUPPORT Human Clinical
"Performance of nephrectomy also trended towards independently improving OS (HR 0.23, 95% CI 0.05-1.09)."
Population-level support for a survival benefit from nephrectomy. PARTIAL because the confidence interval crosses 1 and the authors describe it as a trend rather than a significant independent effect.
PMID:38693188 SUPPORT Human Clinical
"renal sarcomas with positive surgical margin independently demonstrated shorter OS versus R0 resected sarcomas (R + vs. R0, HR = 1.36, 95% CI 1.1–1.68, p = 0.004"
Quantifies why the operative goal is a negative margin rather than resection as such: an R+ resection carries a 36% higher hazard of death than an R0 resection in the same series.
+ 1 more reference
Adjuvant Chemotherapy
Action: chemotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is chemotherapy (NCIT:C15632). NCIT:C15632 is a clinical intervention from the NCI Thesaurus. Ontology label: Chemotherapy NCIT:C15632
Agent: doxorubicin CHEBI:28748 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses doxorubicin (CHEBI:28748). CHEBI:28748 is a therapeutic agent from Chemical Entities of Biological Interest. ifosfamide CHEBI:5864 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses ifosfamide (CHEBI:5864). CHEBI:5864 is a therapeutic agent from Chemical Entities of Biological Interest.
Soft-tissue-sarcoma-directed cytotoxic chemotherapy is given adjuvantly or for metastatic disease, but renal sarcomas are described as chemoresistant and no regimen has established survival benefit in this setting. Regimen choice follows the histological subtype rather than the renal site, which is the practical expression of the driver heterogeneity modeled above: an anthracycline backbone with or without ifosfamide for the complex-karyotype subtypes, and the Ewing-family VDC/IE protocol - vincristine, doxorubicin and cyclophosphamide alternating with ifosfamide and etoposide - for renal Ewing sarcoma. The `therapeutic_agent` bindings here name the anthracycline and the alkylator common to both, not a single regimen, because there is no one regimen for this entry's whole scope.
Show evidence (3 references)
PMID:36591871 SUPPORT Human Clinical
"Adjuvant chemotherapy was administered in 11/12 patients."
Documents adjuvant chemotherapy as near-universal practice in renal synovial sarcoma. PARTIAL because the series reports use, not efficacy.
PMID:32282650 SUPPORT Human Clinical
"vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide (VDC/IE)"
Names the Ewing-family regimen used for the renal Ewing primary, the worked case of regimen choice following histology rather than site. PARTIAL because the series is a small case cohort and does not establish efficacy against an alternative.
PMID:42050503 REFUTE Human Clinical
"They progress rapidly and are resistant to radiotherapy and chemotherapy."
Refutes the expectation of chemotherapy benefit, and is recorded here so the limited efficacy is explicit rather than implied by omission.
Radiation Therapy
Action: radiation therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is radiation therapy (NCIT:C15313). NCIT:C15313 is a clinical intervention from the NCI Thesaurus. Ontology label: Radiation Therapy NCIT:C15313
Renal sarcomas are generally described as radioresistant, and radiotherapy is not standard. The Japanese national registry nonetheless found radiation associated with improved survival on multivariable analysis, which is discordant with the prevailing description and is reported here as an open question rather than a recommendation - the registry cannot adjust for the selection of fitter patients with resectable disease into radiotherapy.
Show evidence (2 references)
PMID:41777120 SUPPORT Human Clinical
"Surgical resection (HR, 0.41; p = 0.004) and radiation therapy (HR, 0.39; p = 0.010) were associated with improved survival."
Reports a survival association for radiation therapy in a national registry cohort, the observation this entry flags as discordant with the standard description of radioresistance.
PMID:42050503 REFUTE Human Clinical
"They progress rapidly and are resistant to radiotherapy and chemotherapy."
The opposing view, stating radioresistance. Retained alongside the registry finding because the discordance is real and unresolved.
🔬

Diagnosis

5
Image-Guided Core Needle Biopsy
A renal mass with classical radiological features usually goes straight to surgery, which is why renal sarcomas are so often diagnosed only after nephrectomy. The registry authors argue that pre-treatment biopsy should instead follow retroperitoneal soft-tissue-sarcoma guidance, particularly for the atypical presentation that raises the suspicion in the first place - a very large, heterogeneous mass infiltrating adjacent organs. Making the diagnosis before surgery is what makes histology-directed neoadjuvant treatment possible at all.
image-guided core needle biopsy NCIT:C15189 NCI Thesaurus (NCIT)
Results: Core needle tissue sufficient for morphology, an immunohistochemical panel, and molecular testing.
Show evidence (1 reference)
PMID:38693188 SUPPORT Human Clinical
"pre-treatment tumor biopsies may play a clinical role for renal sarcoma patients, which would follow guidelines recommending tumor biopsies for the management of retroperitoneal STS"
Supports pre-treatment core biopsy on retroperitoneal soft-tissue-sarcoma principles rather than renal cancer principles.
Immunohistochemical Exclusion of Sarcomatoid Renal Cell Carcinoma
The diagnosis of primary renal sarcoma is one of exclusion, and the entity to exclude is sarcomatoid renal cell carcinoma. Demonstrating epithelial differentiation - cytokeratin and EMA expression, or a recognisable carcinomatous component - reclassifies the tumour as a carcinoma; a true sarcoma is negative for these. This is the test that decides whether checkpoint-inhibitor therapy is on the table.
cytokeratin and EMA immunohistochemistry NCIT:C23020 NCI Thesaurus (NCIT)
Results: Absence of cytokeratin/EMA expression and of a carcinomatous component supports a primary sarcoma; their presence indicates sarcomatoid renal cell carcinoma.
Show evidence (1 reference)
PMID:32491531 SUPPORT Human Clinical
"Since the prognosis for a renal sarcoma is particularly poor, differentiation from sarcomatoid renal cell carcinoma is necessary."
States the diagnostic requirement this entry models, and why it is consequential rather than taxonomic.
MDM2 FISH and CDK4 Immunohistochemistry (renal liposarcoma)
CDK4 expression by immunohistochemistry together with MDM2 amplification by fluorescence in situ hybridization confirms a well-differentiated or dedifferentiated liposarcoma. In the kidney this panel does double duty: it confirms the sarcoma and separates it from angiomyolipoma, the far commoner benign fat-containing renal mass that renal liposarcoma mimics on imaging.
MDM2 fluorescence in situ hybridization NCIT:C17563 NCI Thesaurus (NCIT)
Results: CDK4 expression on immunohistochemistry with MDM2 amplification on FISH.
Show evidence (1 reference)
PMID:38693188 SUPPORT Human Clinical
"The tumor cells demonstrate cdk-4 (inset) and Rb expression by immunohistochemistry as well as mdm-2 amplification by fluorescence in situ hybridization."
Documents the CDK4 immunohistochemistry and MDM2 FISH panel applied to a renal dedifferentiated liposarcoma.
SS18-SSX Immunohistochemistry (renal synovial sarcoma)
A fusion-specific antibody that detects the SS18::SSX product directly. It showed excellent concordance with break-apart FISH across the largest renal synovial sarcoma series, so it is usable as a molecular surrogate where FISH or sequencing is unavailable. Note the series' own caveat: tumours with only focal staining had correspondingly low break-apart signal fractions, so a weak result should prompt confirmatory testing rather than a confident diagnosis.
SS18-SSX immunohistochemistry NCIT:C23020 NCI Thesaurus (NCIT)
Results: Nuclear SS18-SSX expression, diffuse in most cases, indicating SS18::SSX1/2 rearrangement.
Show evidence (1 reference)
PMID:36591871 SUPPORT Human Clinical
"As SS18-SSX IHC showed an excellent concordance with the FISH results, this may reliably be used in the IHC panel of spindle/round cell sarcomas of the kidney and as a molecular surrogate for renal synovial sarcoma, particularly in a resource-limited setting."
Supports SS18-SSX immunohistochemistry as a validated surrogate for FISH in renal synovial sarcoma.
EWSR1 Rearrangement Confirmation (renal Ewing sarcoma)
Small round blue cell morphology in the kidney is shared by renal Ewing sarcoma, the round-cell variant of renal synovial sarcoma, and the paediatric renal tumours excluded from this entry. CD99, FLI1 and NKX2.2 support the diagnosis but do not settle it; demonstrating the EWSR1 rearrangement does.
EWSR1 rearrangement testing NCIT:C17563 NCI Thesaurus (NCIT)
Results: EWSR1 rearrangement, most often EWSR1::FLI1.
Show evidence (1 reference)
PMID:32282650 SUPPORT Human Clinical
"While this malignant process may share histologic and molecular features with its bone and soft tissue counterparts, primary renal ESFT presentations seem to be more aggressive and have worse outcomes."
Supports the renal primary sharing the molecular features that define the Ewing family, which is what confirmatory testing looks for. PARTIAL because the sentence does not itself name the assay.
📊

Prevalence

5
United States adults, SEER and NCDB 2004-2016
Annual Incidence 0.053 per 100,000 <1 in 1,000,000
Average annual age-adjusted incidence of 0.53 cases per million person-years, normalised here to 0.053 per 100,000. The rate was flat across the study period. Leiomyosarcoma was the commonest histiotype at 0.14 per million and malignant rhabdoid tumour second at 0.06 per million. Read this as the incidence of the registry's whole 43-histiotype renal-sarcoma category, not of the six subtypes modeled here: malignant rhabdoid tumour of the kidney is explicitly excluded from this entry, so the rate for the modeled scope is lower than 0.53 per million by an unquantified margin. The same caveat applies to the clear cell sarcoma survival figure quoted on the driver-divergence node. The prevalence_class band is applied to an incidence rate here because the Orphanet bands have no incidence equivalent; read it as an order-of-magnitude tag, not a prevalence claim.
Show evidence (1 reference)
PMID:38693188 SUPPORT Human Clinical
"Leiomyosarcoma (AAIR 0.14 cases/1 million) and malignant rhabdoid tumors (0.06 cases/1 million) were most common."
Source for the histiotype-specific incidence rates within the overall renal-sarcoma incidence.
Adults, United States and international series
Point Prevalence Unknown
Two markedly different figures circulate and this entry records both rather than picking one. Case-report and narrative-review literature states about 1% of renal tumours (some series 1-3%); the largest registry study puts it at 0.25% of renal malignancies. The registry figure should be preferred for the denominator of all renal malignancy - the higher figures are plausibly inflated by referral and publication bias toward large, surgically dramatic tumours in the case-report literature.
Show evidence (2 references)
PMID:38693188 SUPPORT Human Clinical
"Accounting for 0.25% of renal malignancies, renal sarcomas include 43 histiotypes"
Registry-derived share of renal malignancy, the lower and better-powered of the two circulating figures.
PMID:24585347 SUPPORT Human Clinical
"Renal sarcoma represents 1-3% of all renal malignant tumours."
The higher figure as stated in the case-report literature, recorded here because the discrepancy with the registry estimate is itself worth curating. PARTIAL because a single case report is weak support for a population proportion.
Adults worldwide
Point Prevalence Unknown
The commonly cited 1% figure as stated in the recent clinical literature.
Show evidence (1 reference)
PMID:42050503 SUPPORT Human Clinical
"Primary renal sarcomas in adults are rare, accounting for 1% of all renal tumors."
Source for the 1% share of adult renal tumours.
United States, SEER 2004-2015
Cases In Literature Unknown
365 patients with renal sarcoma identified across 12 years of SEER registration, an indication of absolute case volume in a national registry rather than a rate.
Show evidence (1 reference)
PMID:36045013 SUPPORT Human Clinical
"We identified 365 patients; at diagnosis, 104 patients (28.5%) had stage I disease (T1N0M0)"
Gives the absolute case count over the SEER study period.
Japan, National Cancer Registry 2016-2019
Cases In Literature Unknown
235 patients across four years of Japanese national registration.
Show evidence (1 reference)
PMID:41777120 SUPPORT Human Clinical
"Among 235 patients, female sex (HR, 0.43; 95% CI, 0.23-0.83; p = 0.012), older age (≥60 years: HR, 5.87; p < 0.001)"
Gives the Japanese national registry case count and the age and sex effects within it.
📊

Related Datasets

1
CLINICOPATHOLOGIC AND MOLECULAR ANALYSIS OF A BCOR-CCNB3+ UNDIFFERENTIATED SARCOMA OF THE KIDNEY REVEALS SIGNIFICANT EPI-GENETIC ALTERATION geo:GSE188555
human MULTI OMICS
PMID:34819304
A SuperSeries combining mutation, expression, DNA methylation and miRNA profiling of a single BCOR-CCNB3 fusion undifferentiated sarcoma arising in the kidney. Relevance was checked rather than assumed: this is a primary renal mesenchymal malignancy and so falls under this root entry, though the histiotype is not one of the six modeled in has_subtypes. It is a single case, so it describes one tumour rather than the class. Candidates scoring higher on name match in the same search were rejected on relevance - they profile clear cell sarcoma of the kidney and rhabdoid tumour of the kidney, both of which this entry explicitly excludes.
{ }

Source YAML

click to show 
name: Kidney Sarcoma
creation_date: "2026-08-28T00:00:00Z"
description: >-
  Kidney sarcoma is a rare group of primary malignant mesenchymal neoplasms of
  the kidney, accounting for roughly 1-3% of adult renal malignancy. Unlike the
  renal cell carcinomas, which arise from tubular epithelium, these tumours arise
  from the non-epithelial compartments of the organ - the smooth muscle of the
  intrarenal vessels and renal pelvic wall, the renal capsule and perinephric
  connective tissue, the sinus fat, and the vascular endothelium. That
  mesenchymal origin is the entry's organising claim, and everything downstream
  of it follows: no epithelial differentiation means none of the VEGF- and
  mTOR-directed systemic framework built for renal cell carcinoma applies, and
  the tumours are correspondingly resistant to radiotherapy and conventional
  chemotherapy, leaving complete surgical resection as the only treatment that
  reliably changes outcome. Growing in the retroperitoneum, they distend rather
  than obstruct and so reach a large size before producing the non-specific triad
  of flank pain, haematuria and a palpable mass; renal vein and inferior vena
  cava invasion with early haematogenous dissemination is characteristic, and
  survival is markedly worse than for renal cell carcinoma of comparable stage.

  The category is broad: the largest registry series counts 43 histiotypes under
  the renal-sarcoma heading. This entry models the six that account for most
  reported disease - leiomyosarcoma (the commonest), liposarcoma, angiosarcoma
  (the most lethal), synovial sarcoma, rhabdomyosarcoma, and Ewing sarcoma - as
  `has_subtypes`, rather than as a `kb/groupings/` union. See
  `curation_scope_rationale` in the notes on the first pathophysiology node for
  why; briefly, the members share a genuine anatomic-and-clinical pathograph but
  not a driver, and the pan-site histology entries already in the knowledge base
  (Leiomyosarcoma, Liposarcoma, Angiosarcoma, Synovial_Sarcoma) are not scoped to
  the kidney, so a Grouping over them would mis-state their extent.

  Explicitly excluded: sarcomatoid renal cell carcinoma (an epithelial carcinoma
  with mesenchymal-appearing dedifferentiation, which is the principal
  differential and must be excluded by keratin/epithelial-marker
  immunohistochemistry before a primary renal sarcoma is diagnosed), Wilms
  tumour/nephroblastoma, and the paediatric renal tumours clear cell sarcoma of
  the kidney and rhabdoid tumour of the kidney, which have their own entries.
categories:
- Genitourinary Cancer
- Sarcoma
parents:
- kidney cancer
- sarcoma
disease_term:
  preferred_term: kidney sarcoma
  term:
    id: MONDO:0002930
    label: kidney sarcoma
has_subtypes:
- name: Renal LMS
  display_name: Renal Leiomyosarcoma
  description: >-
    The commonest primary renal sarcoma, arising from the smooth muscle of the
    intrarenal blood vessels, the renal capsule, or the renal pelvic wall. Mean
    age at presentation is 50-60 years with a female preponderance. Genomically
    complex rather than fusion-driven, with recurrent loss of TP53, RB1 and ATRX
    pathway function; high rate of local recurrence and haematogenous metastasis.
  subtype_term:
    preferred_term: Kidney Leiomyosarcoma
    term:
      id: NCIT:C6183
      label: Kidney Leiomyosarcoma
  evidence:
  - reference: PMID:32491531
    reference_title: Renal Leiomyosarcoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Renal leiomyosarcoma (LMS) is a rare and aggressive mesenchymal tumor that
      usually arises from the smooth muscle cells of the intrarenal blood vessels
      or the renal pelvis.
    explanation: >-
      Establishes the cell of origin and mesenchymal character of the commonest
      renal sarcoma subtype.
- name: Renal Liposarcoma
  display_name: Renal Liposarcoma
  description: >-
    Adipocytic sarcoma arising from the fat of the renal sinus, capsule or
    perinephric tissue. Its principal diagnostic difficulty is radiological: a
    fat-containing renal mass is far more often a benign angiomyolipoma, and
    well-differentiated renal liposarcoma can be indistinguishable on imaging
    alone. Well-differentiated and dedifferentiated forms carry the 12q13-15
    amplicon containing MDM2 and CDK4, which is the diagnostic discriminator from
    benign lipomatous lesions.
  subtype_term:
    preferred_term: Kidney Liposarcoma
    term:
      id: NCIT:C6185
      label: Kidney Liposarcoma
  evidence:
  - reference: PMID:38312755
    reference_title: Primary renal liposarcoma simulating angiomyolipoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In extremely rare instances, the tumor can arise directly from the fat in
      the epicenter of the kidney, disguised as an angiomyolipoma.
    explanation: >-
      Supports both the adipocytic renal origin of this subtype and the
      angiomyolipoma mimicry that makes it a diagnostic problem.
- name: Renal Angiosarcoma
  display_name: Renal Angiosarcoma
  description: >-
    Endothelial-derived sarcoma of the renal vasculature. The rarest of the
    common subtypes and by a wide margin the most lethal - in the Japanese
    national registry it carried a hazard ratio for death of 12.65 and a 3-year
    survival of 19.0%. Frequently presents with spontaneous haemorrhage into or
    around the tumour, and with direct extension into the renal vein and
    perirenal fat.
  subtype_term:
    preferred_term: Kidney Angiosarcoma
    term:
      id: NCIT:C159205
      label: Kidney Angiosarcoma
  evidence:
  - reference: PMID:41777120
    reference_title: "Clinical Characteristics and Prognostic Factors of Renal Sarcoma: A Japanese National Cancer Registry Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      histologic subtype (angiosarcoma: HR, 12.65; p < 0.001), and distant
      disease (HR, 6.32; p < 0.001) were significant independent prognostic
      factors
    explanation: >-
      Quantifies angiosarcoma histology as an independent adverse prognostic
      factor within renal sarcoma.
- name: Renal Synovial Sarcoma
  display_name: Renal Synovial Sarcoma
  description: >-
    A translocation-driven sarcoma defined by the SS18::SSX1/2 fusion, accounting
    for under 1% of renal sarcomas. Unlike the other subtypes it has a single
    defining genetic lesion, detectable by SS18-SSX immunohistochemistry as a
    surrogate for FISH. Spindle-cell, round-cell and epithelioid morphologies all
    occur, and the round-cell pattern is a recognised mimic of other small
    round-blue-cell renal tumours.
  subtype_term:
    preferred_term: Kidney Synovial Sarcoma
    term:
      id: NCIT:C157737
      label: Kidney Synovial Sarcoma
  evidence:
  - reference: PMID:36591871
    reference_title: "SS18-SSX Expression in a Contemporary Cohort of Primary Renal Synovial Sarcoma: A Multi-Institutional Experience of Fourteen Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Primary renal synovial sarcoma is a rare aggressive mesenchymal neoplasm of
      the kidney that accounts for less than 1% of renal sarcomas.
    explanation: >-
      Establishes renal synovial sarcoma as a distinct, rare mesenchymal subtype
      within renal sarcoma.
- name: Renal RMS
  display_name: Renal Rhabdomyosarcoma
  description: >-
    Skeletal-muscle-differentiated sarcoma of the kidney, extremely rare in
    adults, where it behaves far more aggressively than the paediatric disease.
    Most reported adult cases are embryonal. Because rhabdomyoblastic
    differentiation is not a normal constituent of the kidney, this subtype is
    considered to arise from primitive mesenchyme with divergent myogenic
    differentiation rather than from a resident myocyte population.
  subtype_term:
    preferred_term: Kidney Rhabdomyosarcoma
    term:
      id: NCIT:C159206
      label: Kidney Rhabdomyosarcoma
  evidence:
  - reference: PMID:37753457
    reference_title: "Unique manifestation of primary renal rhabdomyosarcoma in patient with autosomal polycystic kidneys: Case report and review of literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Primary embryonal rhabdomyosarcomas of the kidney are extremely rare,
      especially in adults.
    explanation: >-
      Supports the rarity of this subtype and its predominantly embryonal
      histology in adults.
- name: Renal Ewing Sarcoma
  display_name: Renal Ewing Sarcoma / Primitive Neuroectodermal Tumour
  description: >-
    A small round blue cell sarcoma of the Ewing family arising primarily in the
    kidney, driven by an EWSR1::FLI1 or related ETS-family fusion. It is the one
    subtype for which there is direct evidence that the renal site changes
    behaviour rather than merely relocating a familiar tumour: in a pooled
    analysis of 362 reported cases, metastases were present at diagnosis in 53%
    of renal Ewing sarcoma against 20-25% for the Ewing family overall, and nodal
    disease in 24% against 3.2% for primary skeletal Ewing sarcoma. It presents
    at a much younger age than the other renal sarcomas - adolescents and young
    adults rather than the sixth decade - and is treated on Ewing-family
    multimodal protocols rather than as a renal tumour.
  subtype_term:
    preferred_term: Kidney Ewing Sarcoma
    term:
      id: NCIT:C159208
      label: Kidney Ewing Sarcoma
  evidence:
  - reference: PMID:32282650
    reference_title: Primary Renal Ewing Sarcoma in Children and Young Adults.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Notably, while the general ESFT population has reported rates of metastasis
      at diagnosis of 20% to 25%, this rate in the renal ESFT population was 53%
      with a rate of 59% in adolescent and young-adult patients (11 to 24 y).
    explanation: >-
      Quantifies the excess metastatic burden at diagnosis specific to the renal
      site, the observation on which this subtype's description rests.
pathophysiology:
- name: Malignant Transformation of Renal Mesenchyme
  biological_scale: CELLULAR
  description: >-
    Kidney sarcomas arise by malignant transformation of the non-epithelial
    compartments of the kidney - the smooth muscle of the intrarenal arteries,
    veins and renal pelvic wall; the fibrous capsule and perinephric connective
    tissue; the adipose tissue of the renal sinus; and the vascular endothelium.
    This is the definitional node of the entry and the point at which it diverges
    from every renal cell carcinoma: there is no tubular epithelial precursor and
    no epithelial differentiation programme, so the transformed cell retains a
    mesenchymal phenotype from the outset. Which mesenchymal lineage transforms
    determines the histological subtype, and the transforming lesions differ
    completely between lineages - complex chromosomal loss in leiomyosarcoma and
    angiosarcoma, the 12q13-15 MDM2/CDK4 amplicon in liposarcoma, and the single
    SS18::SSX fusion in synovial sarcoma.
  notes: >-
    curation_scope_rationale: This entry is a root Disease with histological
    `has_subtypes` rather than a `kb/groupings/` union, which was seriously
    considered. Two things decided it. First, the members do share a real
    pathograph, not merely a name: mesenchymal (non-epithelial) origin, silent
    retroperitoneal expansion to large size, renal vein and vena cava invasion
    with early haematogenous spread, and the absence of any epithelial target for
    RCC-directed systemic therapy. That chain is more specific than the generic
    cancer hallmarks and it holds across the subtypes. Second, a Grouping's
    `members[].member` must resolve to an existing entry, and the only candidates
    in the knowledge base (Leiomyosarcoma, Liposarcoma, Angiosarcoma,
    Synovial_Sarcoma) are pan-site histology entries whose extent is not renal;
    listing them as members of "Kidney Sarcoma" would mis-state their scope. This
    is the point of difference from Paranasal_Sinus_Carcinoma, which took the
    Grouping route on very similar anatomic-plus-clinical grounds but already had
    site-specific member entries (Paranasal_Sinus_Squamous_Cell_Carcinoma,
    Ethmoid_Sinus_Adenocarcinoma, Sinonasal_Undifferentiated_Carcinoma) to unite.
    The direct in-KB precedent for the shape adopted here is
    Sarcoma_Of_Cervix_Uteri - a site-specific sarcoma umbrella with equally
    divergent subtype drivers (DICER1 in ERMS, complex karyotype in
    leiomyosarcoma) curated as one Disease with `has_subtypes`. The divergence of
    drivers is handled where it belongs, in per-subtype `genetic:` blocks keyed by
    `subtype:`, not by blending it into shared pathophysiology nodes. If
    site-specific member Disease entries are curated later, revisiting this as a
    Grouping is a reasonable follow-up.
  cell_types:
  - preferred_term: mesenchymal stem cell
    term:
      id: CL:0000134
      label: mesenchymal stem cell
  - preferred_term: vascular smooth muscle cell of the intrarenal vessels
    term:
      id: CL:0000192
      label: smooth muscle cell
  - preferred_term: renal vascular endothelial cell
    term:
      id: CL:0002139
      label: endothelial cell of vascular tree
  - preferred_term: renal sinus adipocyte
    term:
      id: CL:0000136
      label: adipocyte
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:32491531
    reference_title: Renal Leiomyosarcoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Renal leiomyosarcoma (LMS) is a rare and aggressive mesenchymal tumor that
      usually arises from the smooth muscle cells of the intrarenal blood vessels
      or the renal pelvis.
    explanation: >-
      Names the mesenchymal compartments of the kidney - intrarenal vascular
      smooth muscle and renal pelvis - as the site of origin, which is the claim
      this node makes.
  downstream:
  - target: Subtype-Specific Driver Lesion Acquisition
    causal_link_type: DIRECT
    description: >-
      The transformed mesenchymal lineage determines which driver lesion class is
      acquired and therefore which histological subtype results.
  - target: Diagnostic Confusion with Sarcomatoid Renal Cell Carcinoma
    causal_link_type: DIRECT
    description: >-
      The absence of an epithelial differentiation programme is precisely what a
      dedifferentiated renal cell carcinoma mimics morphologically, so mesenchymal
      origin is what has to be demonstrated at diagnosis rather than assumed.
- name: Subtype-Specific Driver Lesion Acquisition
  biological_scale: MOLECULAR
  conforms_to: "genome_instability_mutation#Mutator Phenotype and Chromosomal Instability"
  description: >-
    The genetic route to malignancy is not shared across the subtypes, and this
    node exists to say so explicitly rather than to assert a common driver. Two
    genetic architectures are represented. The majority of renal sarcomas -
    leiomyosarcoma, angiosarcoma and dedifferentiated liposarcoma - are
    genomically complex: they carry aneuploid, structurally rearranged genomes
    produced by loss of tumour-suppressor and genome-maintenance function (TP53,
    RB1, ATRX) rather than by a single positive driver, which is the chromosomal
    instability arm of the genome-instability hallmark. A minority - renal
    synovial sarcoma - is instead fusion-driven, defined by a single SS18::SSX1/2
    translocation on a near-diploid background, and does not conform to the
    mutator phenotype at all. Well-differentiated liposarcoma sits between the two
    with a focal, recurrent amplicon (12q13-15, containing MDM2 and CDK4). This
    heterogeneity is not an annotation artefact: national registry data show
    histological subtype to be the single strongest predictor of survival within
    renal sarcoma, with 3-year survival ranging from 19.0% for angiosarcoma to
    94.4% for clear cell sarcoma of the kidney, and the largest combined
    SEER/NCDB series counts 43 distinct histiotypes under the renal-sarcoma
    heading with differing sensitivity to systemic therapy. The practical
    corollary, and the reason this node is modeled as divergence rather than as a
    shared driver, is that treatment selection follows the histology and not the
    organ.
  biological_processes:
  - preferred_term: DNA repair
    modifier: DECREASED
    term:
      id: GO:0006281
      label: DNA repair
  evidence:
  - reference: PMID:41777120
    reference_title: "Clinical Characteristics and Prognostic Factors of Renal Sarcoma: A Japanese National Cancer Registry Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Histologic subtype is the most critical prognostic factor for renal sarcoma
      in Japan's aging population, with dramatic survival differences: clear cell
      sarcoma (94.4% 3-year survival) versus angiosarcoma (19.0%).
    explanation: >-
      Directly supports the claim that the subtypes are biologically distinct
      rather than variants of one process, quantified as a survival difference of
      75 percentage points at 3 years.
  - reference: PMID:38693188
    reference_title: "Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      renal sarcomas include 43 histiotypes with distinct epidemiology, clinical
      presentation, outcomes and sensitivity to systemic therapy, thereby
      reflecting soft-tissue sarcoma behavior
    explanation: >-
      The largest combined SEER/NCDB series states the driver and behavioural
      heterogeneity this node models, and locates renal sarcoma's behaviour with
      soft-tissue sarcoma rather than with renal cancer.
  - reference: PMID:36591871
    reference_title: "SS18-SSX Expression in a Contemporary Cohort of Primary Renal Synovial Sarcoma: A Multi-Institutional Experience of Fourteen Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All the tumors harbored SS18::SSX1/2 gene rearrangement.
    explanation: >-
      Supports the fusion-driven arm of this node - renal synovial sarcoma is
      uniformly defined by a single translocation - and so supports the claim
      that driver architecture differs between subtypes. PARTIAL because it
      speaks only to the synovial subtype, not to the complex-karyotype majority.
  downstream:
  - target: Silent Retroperitoneal Expansion
    causal_link_type: DIRECT
    description: >-
      Unchecked proliferation of the transformed mesenchymal clone produces the
      expanding retroperitoneal mass.
- name: Silent Retroperitoneal Expansion
  biological_scale: TISSUE
  description: >-
    The kidney sits in a distensible retroperitoneal compartment, and a
    mesenchymal tumour growing within the renal capsule, sinus or perinephric
    tissue displaces structures rather than obstructing them. There is no early
    symptom analogous to the obstructive or bleeding presentation of tumours in a
    lumen, so the tumour is typically large at diagnosis - reported primary renal
    sarcomas are commonly 6-12 cm or greater - and produces only the non-specific
    triad of flank pain, haematuria (when the mass reaches the collecting system)
    and a palpable mass. This delay is the mechanism by which stage at diagnosis,
    itself the dominant prognostic variable, is set: in the SEER cohort stage III
    disease carried a hazard ratio for death of 4.93 against stage I, and median
    survival fell from 105 months to 8 months.
  evidence:
  - reference: PMID:36045013
    reference_title: "Renal Sarcoma: A Population-Based Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Median survival was 105 months (interquartile range [IQR], 29 - not
      reached) for stage I disease, 46 months (IQR 14-118 months) for stage II
      disease, 8 months (IQR 3-28 months) for stage III disease
    explanation: >-
      Quantifies the consequence of the delayed presentation modeled here: stage
      at diagnosis separates median survival by more than an order of magnitude.
  - reference: PMID:34102790
    reference_title: Primary Renal Leiomyosarcoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CT scan revealed an enhancing, heterogeneous, 6×7×9 cm right renal mass.
    explanation: >-
      A representative incidentally detected renal leiomyosarcoma already 9 cm at
      diagnosis, illustrating the large size reached before detection. PARTIAL
      because a single case documents the pattern without establishing its
      frequency.
  - reference: PMID:38693188
    reference_title: "Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients presented with advanced local extent (T3 33.3%; T4 14.2%) or
      distant metastases (29.1%) and commonly underwent surgical resection
      (81.6%).
    explanation: >-
      Quantifies the late presentation this node models at population scale:
      nearly half of adult renal sarcomas are T3 or T4 and almost a third are
      already metastatic when first diagnosed.
  downstream:
  - target: Vascular Invasion and Haematogenous Dissemination
    causal_link_type: DIRECT
    description: >-
      Continued local growth brings the tumour into contact with, and then
      through, the renal venous system.
- name: Vascular Invasion and Haematogenous Dissemination
  biological_scale: TISSUE
  conforms_to: "invasion_and_metastasis#Local Invasion and Intravasation"
  description: >-
    Renal sarcomas invade locally through the perirenal fat and into the renal
    vein, and from there into the inferior vena cava, occasionally as a tumour
    thrombus reaching the right atrium. Because the subtypes originate in or
    adjacent to the renal vasculature, intravasation is anatomically immediate
    rather than a late acquired capability, and dissemination is predominantly
    haematogenous rather than lymphatic - the liver, lung, bone and brain are the
    usual destinations. Note that the epithelial-mesenchymal transition step of
    the invasion-and-metastasis module is deliberately not claimed here: these
    cells are mesenchymal from the outset and never undergo a phenotype switch to
    acquire motility.
  biological_processes:
  - preferred_term: cell migration
    modifier: INCREASED
    term:
      id: GO:0016477
      label: cell migration
  - preferred_term: extracellular matrix organization
    modifier: INCREASED
    term:
      id: GO:0030198
      label: extracellular matrix organization
  evidence:
  - reference: PMID:32491531
    reference_title: Renal Leiomyosarcoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Renal LMS frequently metastasizes to distant body organs via hematogenous
      spread and carries an overall poor prognosis.
    explanation: >-
      Directly supports haematogenous rather than lymphatic dissemination as the
      dominant metastatic route.
  - reference: PMID:30061122
    reference_title: Primary renal angiosarcoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Final pathology was pT2b with extension of the mass into the renal vein and
      perirenal adipose tissue.
    explanation: >-
      Documents the renal vein and perirenal fat invasion that this node models,
      in the angiosarcoma subtype.
  - reference: PMID:42050503
    reference_title: "Anesthetic management of primary renal sarcoma with Mayo IV tumor thrombus using moderate hypothermic circulatory arrest and antegrade cerebral perfusion: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A 49-year-old man was admitted with a left kidney mass and inferior vena
      cava (IVC) tumor thrombus extending into the right atrium (Mayo grade IV).
    explanation: >-
      Documents the extreme of the venous-invasion phenotype modeled here - a
      tumour thrombus propagating from the renal vein through the vena cava to
      the right atrium.
  downstream:
  - target: Absence of Epithelial Therapeutic Target
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Once disease is disseminated, treatment depends on systemic options, and
      the mesenchymal phenotype determines that none of the renal-cell-carcinoma
      options apply.
- name: Absence of Epithelial Therapeutic Target
  biological_scale: ORGANISM
  description: >-
    The therapeutic consequence of the mesenchymal origin. The entire modern
    systemic framework for kidney cancer - VEGF-pathway tyrosine kinase
    inhibition, mTOR inhibition, and PD-1/CTLA-4 checkpoint blockade - was built
    on clear cell renal cell carcinoma biology (VHL loss, hypoxia-inducible
    factor stabilisation, a high-neoantigen immunogenic epithelial tumour) and
    none of it has a target in a renal sarcoma. Conventional soft-tissue sarcoma
    chemotherapy and radiotherapy are correspondingly of limited benefit, so
    complete surgical excision with negative margins is the only intervention
    that reliably alters outcome, and local recurrence after incomplete resection
    is common. This node is the mechanistic reason that kidney sarcoma carries a
    worse prognosis than renal cell carcinoma of equivalent stage, and it is why
    distinguishing the two at diagnosis matters clinically rather than only
    taxonomically.
  evidence:
  - reference: PMID:42050503
    reference_title: "Anesthetic management of primary renal sarcoma with Mayo IV tumor thrombus using moderate hypothermic circulatory arrest and antegrade cerebral perfusion: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They progress rapidly and are resistant to radiotherapy and chemotherapy.
      Currently, surgery is the only effective treatment.
    explanation: >-
      Directly supports the therapeutic corollary of this node - resistance to
      both radiotherapy and chemotherapy, leaving surgery as the only effective
      treatment.
  - reference: PMID:32491531
    reference_title: Renal Leiomyosarcoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There is a high tendency for local recurrence; hence, complete surgical
      excision is recommended.
    explanation: >-
      Supports complete surgical excision as the management principle and local
      recurrence as the failure mode when it is not achieved.
  - reference: PMID:38693188
    reference_title: "Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Renal sarcoma treatment patterns follow recommendations by renal cancer
      guidelines with surgical resection as the cornerstone of therapy.
    explanation: >-
      Confirms surgical resection as the cornerstone of therapy, and documents
      that practice is guided by renal cancer guidelines even though the tumours
      behave as soft-tissue sarcomas - the mismatch this node explains.
- name: Diagnostic Confusion with Sarcomatoid Renal Cell Carcinoma
  biological_scale: TISSUE
  description: >-
    A distinct pathological node rather than a clinical aside, because the two
    entities converge morphologically from opposite directions. A renal sarcoma
    is a mesenchymal tumour that has always been mesenchymal; sarcomatoid renal
    cell carcinoma is an epithelial carcinoma that has undergone
    dedifferentiation to a spindle-cell morphology. On haematoxylin and eosin
    alone a high-grade spindle-cell renal mass is compatible with either, and the
    distinction rests on demonstrating epithelial differentiation - cytokeratin
    and EMA expression, or a recognisable carcinomatous component - which is
    present in sarcomatoid renal cell carcinoma and absent in a true sarcoma. The
    distinction is not academic: sarcomatoid renal cell carcinoma remains a
    carcinoma for therapeutic purposes and retains access to checkpoint-inhibitor
    combinations, whereas a renal sarcoma does not. Sarcomatoid renal cell
    carcinoma is also far commoner, so it is the default diagnosis a spindle-cell
    renal mass must be argued out of.
  evidence:
  - reference: PMID:32491531
    reference_title: Renal Leiomyosarcoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Since the prognosis for a renal sarcoma is particularly poor,
      differentiation from sarcomatoid renal cell carcinoma is necessary.
    explanation: >-
      States the differential-diagnostic requirement this node models and the
      prognostic reason it matters.
  - reference: PMID:26902877
    reference_title: Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      sRCC was associated with a 3.2 higher risk of CSM compared with ccRCC
    explanation: >-
      Characterises the entity a renal sarcoma must be distinguished from -
      sarcomatoid renal cell carcinoma is itself an aggressive epithelial tumour,
      which is why morphology alone cannot separate them on clinical grounds.
      PARTIAL because the paper compares sarcomatoid to clear cell renal cell
      carcinoma and does not address primary renal sarcoma.
  downstream:
  - target: Absence of Epithelial Therapeutic Target
    causal_link_type: DIRECT
    description: >-
      Resolving the differential in favour of a true sarcoma is what commits the
      patient to the therapeutic dead end below - a sarcomatoid renal cell
      carcinoma remains a carcinoma and keeps access to checkpoint-inhibitor
      combinations, a renal sarcoma does not.
phenotypes:
- category: Clinical
  name: Flank Pain
  description: >-
    The commonest presenting symptom, produced by capsular distension and by
    local invasion of the perinephric tissues as the retroperitoneal mass
    enlarges.
  phenotype_term:
    preferred_term: Flank pain
    term:
      id: HP:0030157
      label: Flank pain
  frequency: FREQUENT
  evidence:
  - reference: PMID:30061122
    reference_title: Primary renal angiosarcoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      presented to an outside hospital on 22 February 2017 with acute right flank
      pain
    explanation: >-
      Documents flank pain as the presenting symptom in a primary renal
      angiosarcoma.
- category: Clinical
  name: Palpable Abdominal Mass
  description: >-
    A consequence of the large tumour size typical at diagnosis; renal sarcomas
    are frequently palpable on presentation, which is uncommon for
    contemporaneously diagnosed renal cell carcinoma.
  phenotype_term:
    preferred_term: Palpable renal mass
    term:
      id: HP:0031500
      label: Abdominal mass
  frequency: FREQUENT
  evidence:
  - reference: PMID:34102790
    reference_title: Primary Renal Leiomyosarcoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A 49-year woman was incidentally found to have a palpable mass in the right
      kidney.
    explanation: >-
      Documents a palpable renal mass as the presenting finding in primary renal
      leiomyosarcoma.
- category: Clinical
  name: Hematuria
  description: >-
    Occurs when the expanding mesenchymal mass reaches and breaches the
    pelvicalyceal system. Less consistently present than in urothelial or renal
    cell tumours, because a sarcoma arising in the capsule, sinus fat or
    perinephric tissue may never involve the collecting system.
  phenotype_term:
    preferred_term: Hematuria
    term:
      id: HP:0000790
      label: Hematuria
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:32491531
    reference_title: Renal Leiomyosarcoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Renal leiomyosarcoma (LMS) is a rare and aggressive mesenchymal tumor that
      usually arises from the smooth muscle cells of the intrarenal blood vessels
      or the renal pelvis.
    explanation: >-
      Supports the anatomic premise for this phenotype - a subset of renal
      sarcomas arise in or reach the renal pelvis, which is the route to
      haematuria. PARTIAL because the cited passage establishes the anatomy, not
      the frequency of haematuria.
- category: Clinical
  name: Renal Neoplasm
  description: >-
    The defining structural finding: a solid, often heterogeneous renal or
    perirenal mass, frequently with necrosis and haemorrhage, and radiologically
    indistinguishable from renal cell carcinoma in most cases.
  phenotype_term:
    preferred_term: Renal neoplasm
    term:
      id: HP:0009726
      label: Renal neoplasm
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:30061122
    reference_title: Primary renal angiosarcoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      His pathology revealed a 12.5×6×4.5 cm mass consistent with angiosarcoma of
      the right kidney with negative margins.
    explanation: >-
      Documents the renal mass that defines the presentation, at the large size
      characteristic of this disease.
- category: Clinical
  name: Tumor Hemorrhage
  description: >-
    Spontaneous haemorrhage into or around the tumour, sometimes causing
    haemodynamic instability and requiring embolisation before definitive
    surgery. Particularly characteristic of the angiosarcoma subtype, whose
    neoplastic cells form the vascular channels themselves.
  subtype: Renal Angiosarcoma
  phenotype_term:
    preferred_term: Spontaneous perirenal/tumoral hemorrhage
    term:
      id: HP:0011029
      label: Internal hemorrhage
  evidence:
  - reference: PMID:30061122
    reference_title: Primary renal angiosarcoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      He had a CT scan which revealed a large right renal mass with acute
      haemorrhage. He was initially managed with interventional radiology guided
      embolism on 25 February 2017 due to the ongoing bleeding and haemodynamic
      instability.
    explanation: >-
      Documents spontaneous tumour haemorrhage causing haemodynamic instability
      and requiring embolisation in renal angiosarcoma.
histopathology:
- name: Tumor Necrosis
  finding_term:
    preferred_term: tumor necrosis
    term:
      id: NCIT:C36184
      label: Necrosis
  description: >-
    Coagulative tumour necrosis is common in these large, rapidly growing masses
    that outstrip their blood supply, and it is one of the independent predictors
    of shorter overall survival in the largest registry series. It is also the
    structural substrate of the spontaneous haemorrhage seen in the angiosarcoma
    subtype.
  evidence:
  - reference: PMID:38693188
    reference_title: "Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Longer OS was independently associated with younger age, female sex, lower
      comorbidity index, low T stage, negative surgical margins, absence of tumor
      necrosis or distant metastases and leiomyosarcoma histiotype
    explanation: >-
      Names absence of tumour necrosis as an independent predictor of longer
      survival, so its presence is an adverse histopathological finding.
- name: Pleomorphic Spindle Cell Morphology
  subtype: Renal Liposarcoma
  finding_term:
    preferred_term: dedifferentiated renal liposarcoma morphology
    term:
      id: NCIT:C6185
      label: Kidney Liposarcoma
  description: >-
    Dedifferentiated renal liposarcoma is a non-lipogenic pleomorphic spindle
    cell tumour in a vascular and collagenous stroma. On morphology alone it is
    not separable from other pleomorphic sarcomas, which is why the MDM2/CDK4
    tests carry the diagnosis rather than the histology.
  evidence:
  - reference: PMID:38693188
    reference_title: "Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Core needle biopsy tissue demonstrating dedifferentiated liposarcoma with
      pleomorphic spindle cells within a vascular and collagenous stroma.
    explanation: >-
      Describes the morphology of renal dedifferentiated liposarcoma on core
      needle biopsy.
- name: Small Round Blue Cell Morphology
  subtype: Renal Ewing Sarcoma
  finding_term:
    preferred_term: renal Ewing sarcoma morphology
    term:
      id: NCIT:C159208
      label: Kidney Ewing Sarcoma
  description: >-
    Vaguely lobular sheets of small round blue cells with hyperchromatic nuclei
    and pseudo-rosette formation. This pattern overlaps with the round-cell
    variant of renal synovial sarcoma and with the paediatric renal tumours this
    entry excludes, which is why fusion confirmation is required rather than
    optional.
  evidence:
  - reference: PMID:38693188
    reference_title: "Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Core needle biopsy tissue demonstrating renal PNET with vaguely lobular
      growth of small round blue cells with hyperchromatic nuclei and
      pseudo-rossette formation
    explanation: >-
      Describes the small round blue cell morphology of the renal Ewing/PNET
      primary on core needle biopsy.
- name: Atypical Endothelial-Lined Vascular Spaces
  subtype: Renal Angiosarcoma
  finding_term:
    preferred_term: renal angiosarcoma morphology
    term:
      id: NCIT:C159205
      label: Kidney Angiosarcoma
  description: >-
    Vascular spaces lined by atypical endothelial cells, infiltrating and
    entrapping native renal cortex including glomeruli. The neoplastic cells form
    the vessels themselves, which is the structural reason this subtype bleeds.
  evidence:
  - reference: PMID:38693188
    reference_title: "Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Section from a 19 cm renal angiosarcoma involving the renal cortex with
      entrapped glomeruli. Inset: Higher magnification (400×) demonstrating
      vascular spaces lined by atypical endothelial cells.
    explanation: >-
      Describes the infiltrative growth and atypical endothelial lining that
      define renal angiosarcoma histologically.
diagnosis:
- name: Image-Guided Core Needle Biopsy
  description: >-
    A renal mass with classical radiological features usually goes straight to
    surgery, which is why renal sarcomas are so often diagnosed only after
    nephrectomy. The registry authors argue that pre-treatment biopsy should
    instead follow retroperitoneal soft-tissue-sarcoma guidance, particularly for
    the atypical presentation that raises the suspicion in the first place - a
    very large, heterogeneous mass infiltrating adjacent organs. Making the
    diagnosis before surgery is what makes histology-directed neoadjuvant
    treatment possible at all.
  diagnosis_term:
    preferred_term: image-guided core needle biopsy
    term:
      id: NCIT:C15189
      label: Biopsy Procedure
  results: >-
    Core needle tissue sufficient for morphology, an immunohistochemical panel,
    and molecular testing.
  evidence:
  - reference: PMID:38693188
    reference_title: "Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      pre-treatment tumor biopsies may play a clinical role for renal sarcoma
      patients, which would follow guidelines recommending tumor biopsies for the
      management of retroperitoneal STS
    explanation: >-
      Supports pre-treatment core biopsy on retroperitoneal soft-tissue-sarcoma
      principles rather than renal cancer principles.
- name: Immunohistochemical Exclusion of Sarcomatoid Renal Cell Carcinoma
  description: >-
    The diagnosis of primary renal sarcoma is one of exclusion, and the entity to
    exclude is sarcomatoid renal cell carcinoma. Demonstrating epithelial
    differentiation - cytokeratin and EMA expression, or a recognisable
    carcinomatous component - reclassifies the tumour as a carcinoma; a true
    sarcoma is negative for these. This is the test that decides whether
    checkpoint-inhibitor therapy is on the table.
  diagnosis_term:
    preferred_term: cytokeratin and EMA immunohistochemistry
    term:
      id: NCIT:C23020
      label: Immunohistochemistry Staining Method
  results: >-
    Absence of cytokeratin/EMA expression and of a carcinomatous component
    supports a primary sarcoma; their presence indicates sarcomatoid renal cell
    carcinoma.
  evidence:
  - reference: PMID:32491531
    reference_title: Renal Leiomyosarcoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Since the prognosis for a renal sarcoma is particularly poor,
      differentiation from sarcomatoid renal cell carcinoma is necessary.
    explanation: >-
      States the diagnostic requirement this entry models, and why it is
      consequential rather than taxonomic.
- name: MDM2 FISH and CDK4 Immunohistochemistry (renal liposarcoma)
  description: >-
    CDK4 expression by immunohistochemistry together with MDM2 amplification by
    fluorescence in situ hybridization confirms a well-differentiated or
    dedifferentiated liposarcoma. In the kidney this panel does double duty: it
    confirms the sarcoma and separates it from angiomyolipoma, the far commoner
    benign fat-containing renal mass that renal liposarcoma mimics on imaging.
  diagnosis_term:
    preferred_term: MDM2 fluorescence in situ hybridization
    term:
      id: NCIT:C17563
      label: Fluorescence In Situ Hybridization
  results: >-
    CDK4 expression on immunohistochemistry with MDM2 amplification on FISH.
  evidence:
  - reference: PMID:38693188
    reference_title: "Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The tumor cells demonstrate cdk-4 (inset) and Rb expression by
      immunohistochemistry as well as mdm-2 amplification by fluorescence in situ
      hybridization.
    explanation: >-
      Documents the CDK4 immunohistochemistry and MDM2 FISH panel applied to a
      renal dedifferentiated liposarcoma.
- name: SS18-SSX Immunohistochemistry (renal synovial sarcoma)
  description: >-
    A fusion-specific antibody that detects the SS18::SSX product directly. It
    showed excellent concordance with break-apart FISH across the largest renal
    synovial sarcoma series, so it is usable as a molecular surrogate where FISH
    or sequencing is unavailable. Note the series' own caveat: tumours with only
    focal staining had correspondingly low break-apart signal fractions, so a
    weak result should prompt confirmatory testing rather than a confident
    diagnosis.
  diagnosis_term:
    preferred_term: SS18-SSX immunohistochemistry
    term:
      id: NCIT:C23020
      label: Immunohistochemistry Staining Method
  results: >-
    Nuclear SS18-SSX expression, diffuse in most cases, indicating SS18::SSX1/2
    rearrangement.
  evidence:
  - reference: PMID:36591871
    reference_title: "SS18-SSX Expression in a Contemporary Cohort of Primary Renal Synovial Sarcoma: A Multi-Institutional Experience of Fourteen Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      As SS18-SSX IHC showed an excellent concordance with the FISH results, this
      may reliably be used in the IHC panel of spindle/round cell sarcomas of the
      kidney and as a molecular surrogate for renal synovial sarcoma, particularly
      in a resource-limited setting.
    explanation: >-
      Supports SS18-SSX immunohistochemistry as a validated surrogate for FISH in
      renal synovial sarcoma.
- name: EWSR1 Rearrangement Confirmation (renal Ewing sarcoma)
  description: >-
    Small round blue cell morphology in the kidney is shared by renal Ewing
    sarcoma, the round-cell variant of renal synovial sarcoma, and the paediatric
    renal tumours excluded from this entry. CD99, FLI1 and NKX2.2 support the
    diagnosis but do not settle it; demonstrating the EWSR1 rearrangement does.
  diagnosis_term:
    preferred_term: EWSR1 rearrangement testing
    term:
      id: NCIT:C17563
      label: Fluorescence In Situ Hybridization
  results: >-
    EWSR1 rearrangement, most often EWSR1::FLI1.
  evidence:
  - reference: PMID:32282650
    reference_title: Primary Renal Ewing Sarcoma in Children and Young Adults.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While this malignant process may share histologic and molecular features
      with its bone and soft tissue counterparts, primary renal ESFT
      presentations seem to be more aggressive and have worse outcomes.
    explanation: >-
      Supports the renal primary sharing the molecular features that define the
      Ewing family, which is what confirmatory testing looks for. PARTIAL because
      the sentence does not itself name the assay.
genetic:
- name: SS18
  subtype: Renal Synovial Sarcoma
  gene_term:
    preferred_term: SS18
    term:
      id: hgnc:11340
      label: SS18
  association: Somatic SS18::SSX1/2 translocation
  relationship_type: SOMATIC_DRIVER
  notes: >-
    The defining lesion of renal synovial sarcoma, present in all reported
    cases of the largest contemporary series. The SS18::SSX fusion protein
    misdirects the BAF (SWI/SNF) chromatin-remodelling complex, degrading the
    canonical cBAF complex and driving a fusion-specific transcriptional
    programme. SS18-SSX immunohistochemistry is concordant with FISH and is a
    usable diagnostic surrogate.
  evidence:
  - reference: PMID:36591871
    reference_title: "SS18-SSX Expression in a Contemporary Cohort of Primary Renal Synovial Sarcoma: A Multi-Institutional Experience of Fourteen Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SS18-SSX IHC was positive in all 14 tumors (diffuse, n = 10; multifocal, n
      = 2; focal, n = 2). All the tumors harbored SS18::SSX1/2 gene
      rearrangement.
    explanation: >-
      Establishes the SS18::SSX1/2 rearrangement as universal in this cohort of
      renal synovial sarcoma and validates SS18-SSX immunohistochemistry as a
      surrogate.
- name: SSX1
  subtype: Renal Synovial Sarcoma
  gene_term:
    preferred_term: SSX1
    term:
      id: hgnc:11335
      label: SSX1
  association: Somatic fusion partner in SS18::SSX1 translocation
  relationship_type: SOMATIC_DRIVER
  notes: >-
    The X-linked partner gene of the defining translocation; SS18::SSX1 and
    SS18::SSX2 are the two recurrent fusions, and the multi-institutional renal
    series did not distinguish which partner predominates in the kidney.
  evidence:
  - reference: PMID:36591871
    reference_title: "SS18-SSX Expression in a Contemporary Cohort of Primary Renal Synovial Sarcoma: A Multi-Institutional Experience of Fourteen Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All the tumors harbored SS18::SSX1/2 gene rearrangement.
    explanation: >-
      Names SSX1/2 as the fusion partner in every tumour of the renal synovial
      sarcoma cohort.
- name: TP53
  subtype: Renal LMS
  gene_term:
    preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  association: Somatic loss-of-function mutation and deletion
  relationship_type: SOMATIC_DRIVER
  notes: >-
    Leiomyosarcoma has no defining fusion. Its genome is complex, with recurrent
    inactivation of TP53, RB1 and ATRX, and this architecture is what places the
    subtype in the chromosomal-instability arm of the pathophysiology rather than
    the fusion-driven arm. Important caveat on the evidence: this driver
    spectrum is established for leiomyosarcoma at other sites - the cited work is
    on uterine leiomyosarcoma, where the tumour is common enough to sequence -
    and has not been separately confirmed in the renal primary, which is one
    instance of the site-versus-molecular-correlate gap recorded in the
    discussions. Curated here because it is the best available account of this
    subtype's driver class, not because a renal cohort has been sequenced.
  evidence:
  - reference: PMID:29660202
    reference_title: Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      whole-exome sequencing of u-LMS has confirmed and demonstrated frequent
      alterations in TP53, RB1, α-thalassemia/mental retardation syndrome X-linked
      (ATRX) and mediator complex subunit 12 (MED12)
    explanation: >-
      Establishes TP53, RB1 and ATRX as the recurrent alterations of
      leiomyosarcoma. PARTIAL, and deliberately so: the cohort is uterine
      leiomyosarcoma, not renal, so this supports the histology's driver class
      rather than a renal-specific finding. Graded HUMAN_CLINICAL because what the
      paper reports is human tumour genomics - TCGA and whole-exome sequencing of
      patient tumours - even though its format is a review.
- name: RB1
  subtype: Renal LMS
  gene_term:
    preferred_term: RB1
    term:
      id: hgnc:9884
      label: RB1
  association: Somatic loss-of-function mutation and deletion
  relationship_type: SOMATIC_DRIVER
  notes: >-
    Co-inactivated with TP53 in the complex-karyotype leiomyosarcoma genome. Same
    site caveat as the TP53 entry: established in uterine leiomyosarcoma, not
    separately confirmed in renal primaries.
  evidence:
  - reference: PMID:29660202
    reference_title: Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In 2017, The Cancer Genome Atlas (TCGA) Research Network's work on u-LMS has
      confirmed mutations and deletions in RB1, TP53 and PTEN.
    explanation: >-
      TCGA confirmation of RB1 mutation and deletion in leiomyosarcoma. PARTIAL
      because the cohort is uterine rather than renal. HUMAN_CLINICAL because TCGA
      is human tumour sequencing.
- name: ATRX
  subtype: Renal LMS
  gene_term:
    preferred_term: ATRX
    term:
      id: hgnc:886
      label: ATRX
  association: Somatic loss-of-function mutation
  relationship_type: SOMATIC_DRIVER
  notes: >-
    ATRX loss underlies the alternative-lengthening-of-telomeres phenotype seen in
    complex-karyotype sarcomas and is associated with poor prognosis in
    leiomyosarcoma. Same site caveat as the other two.
  evidence:
  - reference: PMID:29660202
    reference_title: Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TP53 and ATRX mutations can be important mechanisms in the pathogenesis of
      u-LMS and are correlated with a poor prognosis.
    explanation: >-
      Supports ATRX mutation as a pathogenic mechanism in leiomyosarcoma with
      prognostic weight. PARTIAL because the cohort is uterine rather than renal.
      HUMAN_CLINICAL because the underlying data are human tumour sequencing.
- name: MDM2
  subtype: Renal Liposarcoma
  gene_term:
    preferred_term: MDM2
    term:
      id: hgnc:6973
      label: MDM2
  association: Somatic high-level 12q13-15 amplification
  relationship_type: SOMATIC_DRIVER
  notes: >-
    The 12q13-15 amplicon containing MDM2 and CDK4 defines well-differentiated
    and dedifferentiated liposarcoma and is the diagnostic discriminator from
    benign lipomatous lesions - which is exactly the discrimination a renal
    fat-containing mass requires, since angiomyolipoma is far commoner. As with
    the leiomyosarcoma drivers, this is established for the histology generally
    rather than in a renal cohort.
  evidence:
  - reference: PMID:30852045
    reference_title: "Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      both are associated with high-level amplifications in the chromosomal
      12q13-15 region, which includes the CDK4 and MDM2 cell cycle oncogenes
    explanation: >-
      Establishes the MDM2/CDK4 amplicon as the shared genetic aberration of
      well-differentiated and dedifferentiated liposarcoma. PARTIAL because the
      review covers liposarcoma at all sites, predominantly retroperitoneal and
      extremity, rather than the renal primary. HUMAN_CLINICAL because the
      amplification data it summarises come from human tumour cytogenetics.
- name: CDK4
  subtype: Renal Liposarcoma
  gene_term:
    preferred_term: CDK4
    term:
      id: hgnc:1773
      label: CDK4
  association: Somatic high-level 12q13-15 amplification
  relationship_type: SOMATIC_DRIVER
  notes: >-
    Co-amplified with MDM2 in the same 12q13-15 amplicon; CDK4 immunohistochemistry
    and MDM2 FISH are the routine diagnostic tests for this subtype.
  evidence:
  - reference: PMID:30852045
    reference_title: "Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      WDL and DDL share similar background genetic aberrations; both are
      associated with high-level amplifications in the chromosomal 12q13-15
      region, which includes the CDK4 and MDM2 cell cycle oncogenes.
    explanation: >-
      Names CDK4 within the defining 12q13-15 amplicon. PARTIAL because the
      review is not renal-specific. HUMAN_CLINICAL because the underlying
      amplification data come from human tumours.
- name: EWSR1
  subtype: Renal Ewing Sarcoma
  gene_term:
    preferred_term: EWSR1
    term:
      id: hgnc:3508
      label: EWSR1
  association: Somatic EWSR1::FLI1 (or related ETS-family) translocation
  relationship_type: SOMATIC_DRIVER
  notes: >-
    The defining rearrangement of the Ewing sarcoma family of tumours, shared by
    the renal primary. Molecular confirmation is required for the diagnosis
    because the small round blue cell morphology overlaps with other renal
    tumours, including the round-cell pattern of renal synovial sarcoma.
  evidence:
  - reference: PMID:32282650
    reference_title: Primary Renal Ewing Sarcoma in Children and Young Adults.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While this malignant process may share histologic and molecular features
      with its bone and soft tissue counterparts, primary renal ESFT
      presentations seem to be more aggressive and have worse outcomes.
    explanation: >-
      States that renal Ewing sarcoma shares the molecular features of the Ewing
      family - the EWSR1 rearrangement - while behaving more aggressively.
      PARTIAL because the quoted sentence asserts shared molecular features
      without naming the fusion partner.
- name: FLI1
  subtype: Renal Ewing Sarcoma
  gene_term:
    preferred_term: FLI1
    term:
      id: hgnc:3749
      label: FLI1
  association: Somatic fusion partner in EWSR1::FLI1 translocation
  relationship_type: SOMATIC_DRIVER
  notes: >-
    The commonest ETS-family partner in the Ewing fusion; FLI1
    immunohistochemistry is among the supportive markers used before molecular
    confirmation.
  evidence:
  - reference: PMID:32282650
    reference_title: Primary Renal Ewing Sarcoma in Children and Young Adults.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The Ewing sarcoma family of tumors (ESFT) are high-grade small round blue
      cell malignancies traditionally presenting in children and adolescents.
    explanation: >-
      Establishes the tumour family in which the EWSR1::FLI1 fusion is the
      defining lesion, and its age distribution. PARTIAL because the abstract
      does not itself name FLI1.
treatments:
- name: Radical Nephrectomy with Complete Surgical Excision
  description: >-
    The only intervention that reliably alters outcome. Radical nephrectomy with
    en-bloc resection of involved perinephric tissue and negative margins is the
    standard of care; where a renal vein or vena caval tumour thrombus is
    present, thrombectomy is performed with it, and a Mayo grade IV thrombus
    reaching the right atrium may require cardiopulmonary bypass with hypothermic
    circulatory arrest. Incomplete excision is followed by a high rate of local
    recurrence.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Radical Nephrectomy
    term:
      id: NCIT:C51778
      label: Radical Nephrectomy
  target_mechanisms:
  - target: Silent Retroperitoneal Expansion
    description: >-
      Removes the primary mass and its retroperitoneal extensions before further
      local progression.
  evidence:
  - reference: PMID:42050503
    reference_title: "Anesthetic management of primary renal sarcoma with Mayo IV tumor thrombus using moderate hypothermic circulatory arrest and antegrade cerebral perfusion: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They progress rapidly and are resistant to radiotherapy and chemotherapy.
      Currently, surgery is the only effective treatment.
    explanation: >-
      States that surgery is the only effective treatment for primary renal
      sarcoma, which is the basis of this entry.
  - reference: PMID:36045013
    reference_title: "Renal Sarcoma: A Population-Based Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Performance of nephrectomy also trended towards independently improving OS
      (HR 0.23, 95% CI 0.05-1.09).
    explanation: >-
      Population-level support for a survival benefit from nephrectomy. PARTIAL
      because the confidence interval crosses 1 and the authors describe it as a
      trend rather than a significant independent effect.
  - reference: PMID:38693188
    reference_title: "Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      renal sarcomas with positive surgical margin independently demonstrated
      shorter OS versus R0 resected sarcomas (R + vs. R0, HR = 1.36, 95% CI
      1.1–1.68, p = 0.004
    explanation: >-
      Quantifies why the operative goal is a negative margin rather than
      resection as such: an R+ resection carries a 36% higher hazard of death
      than an R0 resection in the same series.
  - reference: PMID:38693188
    reference_title: "Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While surgical margins were assessed as R + in 21.3% among all surgically
      treated patients (n = 222/1044), a higher frequency of positive surgical
      margins was reported in T4 sarcoma cases undergoing surgical treatment
      (n = 52/128; 40.6%).
    explanation: >-
      Shows how often the negative margin is not achieved - one resection in five
      overall, and two in five for T4 disease - which is the practical limit on
      the only effective treatment.
- name: Adjuvant Chemotherapy
  description: >-
    Soft-tissue-sarcoma-directed cytotoxic chemotherapy is given adjuvantly or
    for metastatic disease, but renal sarcomas are described as chemoresistant and
    no regimen has established survival benefit in this setting. Regimen choice
    follows the histological subtype rather than the renal site, which is the
    practical expression of the driver heterogeneity modeled above: an
    anthracycline backbone with or without ifosfamide for the complex-karyotype
    subtypes, and the Ewing-family VDC/IE protocol - vincristine, doxorubicin and
    cyclophosphamide alternating with ifosfamide and etoposide - for renal Ewing
    sarcoma. The `therapeutic_agent` bindings here name the anthracycline and the
    alkylator common to both, not a single regimen, because there is no one
    regimen for this entry's whole scope.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
    therapeutic_agent:
    - preferred_term: doxorubicin
      term:
        id: CHEBI:28748
        label: doxorubicin
    - preferred_term: ifosfamide
      term:
        id: CHEBI:5864
        label: ifosfamide
  evidence:
  - reference: PMID:36591871
    reference_title: "SS18-SSX Expression in a Contemporary Cohort of Primary Renal Synovial Sarcoma: A Multi-Institutional Experience of Fourteen Patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Adjuvant chemotherapy was administered in 11/12 patients.
    explanation: >-
      Documents adjuvant chemotherapy as near-universal practice in renal
      synovial sarcoma. PARTIAL because the series reports use, not efficacy.
  - reference: PMID:32282650
    reference_title: Primary Renal Ewing Sarcoma in Children and Young Adults.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide
      and etoposide (VDC/IE)
    explanation: >-
      Names the Ewing-family regimen used for the renal Ewing primary, the
      worked case of regimen choice following histology rather than site.
      PARTIAL because the series is a small case cohort and does not establish
      efficacy against an alternative.
  - reference: PMID:42050503
    reference_title: "Anesthetic management of primary renal sarcoma with Mayo IV tumor thrombus using moderate hypothermic circulatory arrest and antegrade cerebral perfusion: a case report."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They progress rapidly and are resistant to radiotherapy and chemotherapy.
    explanation: >-
      Refutes the expectation of chemotherapy benefit, and is recorded here so
      the limited efficacy is explicit rather than implied by omission.
- name: Radiation Therapy
  description: >-
    Renal sarcomas are generally described as radioresistant, and radiotherapy is
    not standard. The Japanese national registry nonetheless found radiation
    associated with improved survival on multivariable analysis, which is
    discordant with the prevailing description and is reported here as an open
    question rather than a recommendation - the registry cannot adjust for the
    selection of fitter patients with resectable disease into radiotherapy.
  therapeutic_modality: RADIOTHERAPY
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: NCIT:C15313
      label: Radiation Therapy
  evidence:
  - reference: PMID:41777120
    reference_title: "Clinical Characteristics and Prognostic Factors of Renal Sarcoma: A Japanese National Cancer Registry Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Surgical resection (HR, 0.41; p = 0.004) and radiation therapy (HR, 0.39; p
      = 0.010) were associated with improved survival.
    explanation: >-
      Reports a survival association for radiation therapy in a national registry
      cohort, the observation this entry flags as discordant with the standard
      description of radioresistance.
  - reference: PMID:42050503
    reference_title: "Anesthetic management of primary renal sarcoma with Mayo IV tumor thrombus using moderate hypothermic circulatory arrest and antegrade cerebral perfusion: a case report."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They progress rapidly and are resistant to radiotherapy and chemotherapy.
    explanation: >-
      The opposing view, stating radioresistance. Retained alongside the registry
      finding because the discordance is real and unresolved.
prevalence:
- population: United States adults, SEER and NCDB 2004-2016
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BELOW_1_IN_1000000
  rate_per_100000: 0.053
  notes: >-
    Average annual age-adjusted incidence of 0.53 cases per million person-years,
    normalised here to 0.053 per 100,000. The rate was flat across the study
    period. Leiomyosarcoma was the commonest histiotype at 0.14 per million and
    malignant rhabdoid tumour second at 0.06 per million. Read this as the
    incidence of the registry's whole 43-histiotype renal-sarcoma category, not
    of the six subtypes modeled here: malignant rhabdoid tumour of the kidney is
    explicitly excluded from this entry, so the rate for the modeled scope is
    lower than 0.53 per million by an unquantified margin. The same caveat
    applies to the clear cell sarcoma survival figure quoted on the
    driver-divergence node. The prevalence_class band is applied to an incidence
    rate here because the Orphanet bands have no incidence equivalent; read it as
    an order-of-magnitude tag, not a prevalence claim.
  evidence:
  - reference: PMID:38693188
    reference_title: "Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Leiomyosarcoma (AAIR 0.14 cases/1 million) and malignant rhabdoid tumors
      (0.06 cases/1 million) were most common.
    explanation: >-
      Source for the histiotype-specific incidence rates within the overall
      renal-sarcoma incidence.
- population: Adults, United States and international series
  measure_type: POINT_PREVALENCE
  prevalence_class: UNKNOWN
  notes: >-
    Two markedly different figures circulate and this entry records both rather
    than picking one. Case-report and narrative-review literature states about 1%
    of renal tumours (some series 1-3%); the largest registry study puts it at
    0.25% of renal malignancies. The registry figure should be preferred for the
    denominator of all renal malignancy - the higher figures are plausibly
    inflated by referral and publication bias toward large, surgically dramatic
    tumours in the case-report literature.
  evidence:
  - reference: PMID:38693188
    reference_title: "Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Accounting for 0.25% of renal malignancies, renal sarcomas include 43
      histiotypes
    explanation: >-
      Registry-derived share of renal malignancy, the lower and better-powered of
      the two circulating figures.
  - reference: PMID:24585347
    reference_title: "[Primary renal rhabdomyosarcoma: a case report]."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Renal sarcoma represents 1-3% of all renal malignant tumours.
    explanation: >-
      The higher figure as stated in the case-report literature, recorded here
      because the discrepancy with the registry estimate is itself worth
      curating. PARTIAL because a single case report is weak support for a
      population proportion.
- population: Adults worldwide
  measure_type: POINT_PREVALENCE
  prevalence_class: UNKNOWN
  notes: >-
    The commonly cited 1% figure as stated in the recent clinical literature.
  evidence:
  - reference: PMID:42050503
    reference_title: "Anesthetic management of primary renal sarcoma with Mayo IV tumor thrombus using moderate hypothermic circulatory arrest and antegrade cerebral perfusion: a case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Primary renal sarcomas in adults are rare, accounting for 1% of all renal
      tumors.
    explanation: >-
      Source for the 1% share of adult renal tumours.
- population: United States, SEER 2004-2015
  measure_type: CASES_IN_LITERATURE
  prevalence_class: UNKNOWN
  notes: >-
    365 patients with renal sarcoma identified across 12 years of SEER
    registration, an indication of absolute case volume in a national registry
    rather than a rate.
  evidence:
  - reference: PMID:36045013
    reference_title: "Renal Sarcoma: A Population-Based Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified 365 patients; at diagnosis, 104 patients (28.5%) had stage I
      disease (T1N0M0)
    explanation: >-
      Gives the absolute case count over the SEER study period.
- population: Japan, National Cancer Registry 2016-2019
  measure_type: CASES_IN_LITERATURE
  prevalence_class: UNKNOWN
  notes: >-
    235 patients across four years of Japanese national registration.
  evidence:
  - reference: PMID:41777120
    reference_title: "Clinical Characteristics and Prognostic Factors of Renal Sarcoma: A Japanese National Cancer Registry Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among 235 patients, female sex (HR, 0.43; 95% CI, 0.23-0.83; p = 0.012),
      older age (≥60 years: HR, 5.87; p < 0.001)
    explanation: >-
      Gives the Japanese national registry case count and the age and sex effects
      within it.
datasets:
- accession: geo:GSE188555
  title: >-
    CLINICOPATHOLOGIC AND MOLECULAR ANALYSIS OF A BCOR-CCNB3+ UNDIFFERENTIATED
    SARCOMA OF THE KIDNEY REVEALS SIGNIFICANT EPI-GENETIC ALTERATION
  data_type: MULTI_OMICS
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  publication: PMID:34819304
  notes: >-
    A SuperSeries combining mutation, expression, DNA methylation and miRNA
    profiling of a single BCOR-CCNB3 fusion undifferentiated sarcoma arising in
    the kidney. Relevance was checked rather than assumed: this is a primary
    renal mesenchymal malignancy and so falls under this root entry, though the
    histiotype is not one of the six modeled in has_subtypes. It is a single
    case, so it describes one tumour rather than the class. Candidates scoring
    higher on name match in the same search were rejected on relevance - they
    profile clear cell sarcoma of the kidney and rhabdoid tumour of the kidney,
    both of which this entry explicitly excludes.
discussions:
- discussion_id: renal_sarcoma_radiotherapy_discordance
  kind: KNOWLEDGE_GAP
  attaches_to:
  - treatments#Radiation Therapy
  prompt: >-
    Is radiotherapy genuinely active in primary renal sarcoma, or is the registry
    survival association an artefact of selecting fitter patients with resectable
    disease?
  rationale: >-
    The literature consistently describes renal sarcoma as radioresistant, yet
    the Japanese national registry found radiation therapy independently
    associated with improved survival (HR 0.39, p = 0.010) on multivariable
    analysis. Registry analyses cannot adjust for performance status, resection
    completeness, or the clinical reasoning that led to radiotherapy being
    offered, so the two observations are not necessarily in conflict - but the
    discordance is unresolved and matters, because it is the difference between
    a treatment with no role and one that is being under-used in a disease with
    almost no systemic options.
- discussion_id: renal_site_molecular_correlate
  kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Subtype-Specific Driver Lesion Acquisition
  prompt: >-
    Does arising in the kidney change the biology of a given sarcoma histology,
    or is renal site purely an anatomical accident with no molecular correlate?
  rationale: >-
    Everything modeled in this entry as shared across subtypes is anatomical and
    clinical - retroperitoneal silent growth, renal venous invasion, absence of
    an epithelial therapeutic target - and nothing is established as shared at
    the molecular level. There is one partial answer, and it points toward the
    site mattering: renal Ewing sarcoma is metastatic at diagnosis in 53% of
    pooled reported cases against 20-25% for the Ewing family overall, and has
    nodal disease in 24% against 3.2% for skeletal primaries, despite carrying
    the same defining fusion. Whether that reflects a genuine microenvironmental
    effect, the vascular anatomy of the kidney, or simply later detection in a
    silent compartment is unresolved - and the equivalent comparison has never
    been made for the commoner subtypes. No study has compared the genomes of
    renal leiomyosarcoma or renal angiosarcoma with their much commoner
    counterparts at other sites. If the site has no molecular correlate, the case
    for a site-based entry rests entirely on the clinical pathograph; if it does,
    the shared node set should grow. This is the empirical question underlying
    the lump-versus-split decision recorded on the first pathophysiology node.
- discussion_id: renal_vs_sts_guideline_mismatch
  kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Absence of Epithelial Therapeutic Target
  - treatments#Adjuvant Chemotherapy
  prompt: >-
    Does managing primary renal sarcoma under renal cancer guidelines rather than
    soft-tissue sarcoma guidelines cost survival, and by how much?
  rationale: >-
    The largest registry series found that renal sarcomas behave as soft-tissue
    sarcomas but are treated according to renal cancer guidelines. If the two
    frameworks agreed on management the observation would be of no consequence,
    but they do not: soft-tissue sarcoma practice routes patients to a sarcoma
    reference centre, selects the cytotoxic regimen by histiotype, and considers
    neoadjuvant therapy for large high-grade tumours, none of which follows from
    a renal cancer pathway. No study has compared outcomes between patients
    managed under the two frameworks, and because the disease is too rare for a
    randomised trial the answer would have to come from a registry analysis
    stratified by whether care was delivered at a sarcoma centre. Until then the
    size of the gap between how these tumours behave and how they are treated is
    unmeasured.
- discussion_id: no_renal_sarcoma_molecular_dataset
  kind: KNOWLEDGE_GAP
  attaches_to:
  - datasets#
  - pathophysiology#Subtype-Specific Driver Lesion Acquisition
  prompt: >-
    Is there any public molecular dataset of primary renal sarcoma, and if not,
    what is the smallest cohort that would settle whether the renal site has a
    molecular signature?
  rationale: >-
    This entry carries one `datasets:` record, and what is missing around it is
    the finding. A GEO sweep for renal sarcoma and its named subtypes returns
    exactly one series profiling a tumour this entry covers - a single
    BCOR-CCNB3 undifferentiated sarcoma of the kidney. Everything else that
    scores highly on name match profiles clear cell sarcoma of the kidney or
    rhabdoid tumour of the kidney, both explicitly excluded here, and the
    remainder mention the search terms only incidentally. There is no molecular
    dataset at all for renal leiomyosarcoma, the commonest histiotype, nor for
    renal angiosarcoma, the most lethal. At an incidence of 0.53 cases per
    million person-years spread across 43 histiotypes, no single institution
    accumulates enough tissue to profile, so the gap is structural rather than
    accidental. It is also the reason the site-versus-molecular-correlate
    question above cannot currently be answered: the comparison needs renal and
    non-renal cases of the same histiotype sequenced together, and that cohort
    would have to be assembled prospectively across a sarcoma consortium. Any
    accession added here in future must be checked for relevance rather than
    accepted because it resolves; searching a causal gene or relaxing the disease
    name in this space returns Wilms tumour, clear cell sarcoma of the kidney and
    sarcomatoid renal cell carcinoma, none of which is this disease.
classifications:
  icdo_morphology:
    classification_value: Sarcoma
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
📚

References & Deep Research

Deep Research

1
Falcon ▸
Kidney Sarcoma: Comprehensive Disease-Characteristics Report
Edison Scientific Literature 17 citations 2026-08-28T17:05:12.646252

Kidney Sarcoma: Comprehensive Disease-Characteristics Report

Evidence cut-off: December 2024, with emphasis on 2023–2024 literature. Scope: “Kidney sarcoma” is an umbrella category rather than one molecular disease. Evidence is dominated by retrospective registries, small series, and extrapolation from histology-matched soft-tissue sarcoma (STS); prospective kidney-sarcoma-specific trials are essentially absent.

Executive summary

Primary renal sarcomas are malignant mesenchymal tumors arising in the kidney, renal capsule, sinus, vessels, or supporting soft tissue. They must not be conflated with sarcomatoid renal-cell carcinoma, an epithelial carcinoma showing mesenchymal-appearing dedifferentiation, or with clear cell sarcoma of kidney (CCSK), a specific pediatric tumor. The strongest contemporary epidemiologic study—1,279 adults in SEER/NCDB, published May 2024—found an age-adjusted incidence of 0.53 per million persons/year, accounting for 0.25% of renal malignancies, but encompassing 43 histotypes. Median overall survival was approximately 25 months. At presentation, 33.3% were T3, 14.2% T4, and 29.1% metastatic; 81.6% underwent surgery. Histotype, stage, metastasis, necrosis, surgical margin, age, sex, and comorbidity materially affected survival. (uhlig2024epidemiologytreatmentand pages 1-2, uhlig2024epidemiologytreatmentand pages 5-7, uhlig2024epidemiologytreatmentand pages 9-10)

The authoritative interpretation is therefore histology-first management at a sarcoma reference center, not uniform treatment as kidney cancer. The 2024 investigators concluded that renal sarcomas “include 43 histiotypes with distinct epidemiology, clinical presentation, outcomes and sensitivity to systemic therapy,” and observed that real-world care frequently followed renal-cancer rather than STS principles. (uhlig2024epidemiologytreatmentand pages 1-2, uhlig2024epidemiologytreatmentand pages 7-9)

1. Disease information

Definition, category, and identifiers

  • Preferred name: kidney sarcoma; common clinical synonym: primary renal sarcoma.
  • Category: rare malignant mesenchymal neoplasm of the kidney; an anatomic umbrella containing multiple WHO-defined STS histotypes.
  • MONDO: MONDO:0002930 — kidney sarcoma. Open Targets recognizes it as a distinct disease entity. (OpenTargets Search: kidney sarcoma)
  • Related but distinct: MONDO:0005006 — clear cell sarcoma of kidney; MONDO:0010434 — synovial sarcoma. (OpenTargets Search: kidney sarcoma)
  • MeSH: generally indexed through Sarcoma, Kidney Neoplasms, and the specific histotype; a unique kidney-sarcoma MeSH heading is not consistently used.
  • ICD-10-CM: no histologically precise single code. Registries commonly combine site C64.-, malignant neoplasm of kidney except renal pelvis, with an ICD-O-3 morphology code such as leiomyosarcoma 8890/3, angiosarcoma 9120/3, synovial sarcoma 9040–9043/3, or Ewing sarcoma 9260/3.
  • ICD-11: coded by malignant kidney site plus morphology/histopathology; local coding systems should retain both dimensions.
  • OMIM/Orphanet: no single inherited-disorder entry adequately represents the heterogeneous adult umbrella. Individual molecular subtypes may have separate disease records.

Important exclusions: Sarcomatoid RCC is not a sarcoma; it can occur in most RCC subtypes, represents about 4% of all RCC but approximately 20% of metastatic RCC, and is WHO/ISUP grade 4. Its biology and checkpoint-based RCC treatment differ from primary renal sarcoma. CCSK is likewise a distinct childhood renal tumor with BCOR-family biology. (OpenTargets Search: kidney sarcoma)

Evidence provenance: The principal quantitative evidence is aggregated disease-level registry data, not individual EHR records. SEER and NCDB provide de-identified population/hospital-level observations; case reports and institutional series contribute individual-patient evidence. (uhlig2024epidemiologytreatmentand pages 1-2, uhlig2024epidemiologytreatmentand pages 9-10)

2. Etiology, risk, and protective factors

Causal factors

Most cases are sporadic cancers caused by acquired somatic alterations. There is no single causal gene for “kidney sarcoma.” Instead, causal events depend on histotype: SS18::SSX in synovial sarcoma, EWSR1::FLI1 or related ETS fusion in Ewing sarcoma, BCOR internal tandem duplication or YWHAE::NUTM2 in CCSK, and EWSR1::CREB3L1 in sclerosing epithelioid fibrosarcoma. These are generally tumor-defining somatic rearrangements, not inherited alleles. (OpenTargets Search: kidney sarcoma, bradford2020primaryrenalewing pages 7-7, baydar2015primarysclerosingepithelioid pages 12-12)

Risk factors

  • Age and sex: these are demographic associations, not proven causes. Adult renal sarcoma had median age about 60 years; renal leiomyosarcoma (LMS) occurred at a median of 62, whereas renal PNET/Ewing-family tumors occurred much younger, around 33 in the registry. LMS was female-predominant (male:female ratio 0.46), while angiosarcoma was male-predominant (3.82). (uhlig2024epidemiologytreatmentand pages 3-5, uhlig2024epidemiologytreatmentand pages 7-9)
  • Ionizing radiation and hereditary cancer predisposition: recognized general STS risks, but kidney-specific attributable risks have not been quantified in modern cohorts.
  • Smoking, obesity, hepatitis C, asbestos, VHL, Birt–Hogg–Dubé, and hereditary papillary RCC: these are established or proposed renal carcinoma associations and should not be automatically assigned to primary renal sarcoma. A renal-tumor educational review lists them together, but it does not establish histotype-specific causality; this is a key evidence-quality limitation. (mohd2022etiologiesgrossappearance pages 9-10)
  • Infectious causes: none established for conventional primary renal sarcoma. EBV-associated smooth-muscle tumors may occur under profound immunosuppression, but they are a separate clinicopathologic context.
  • Gene–environment interaction: no replicated renal-sarcoma-specific G×E interaction has been demonstrated.

Protective factors

No genetic variant, diet, drug, lifestyle behavior, vaccine, or occupational intervention has been shown specifically to prevent primary renal sarcoma. General avoidance of unnecessary ionizing radiation and tobacco is reasonable health policy but is not evidence-based kidney-sarcoma prophylaxis.

3. Phenotypes

Clinical manifestations reflect an enlarging renal/retroperitoneal mass and metastatic spread. Frequencies are incompletely reported because histotypes are rare and registry symptom fields are limited.

  • Renal/abdominal mass — usually adult or adolescent onset according to subtype; often large and progressive. Suggested HPO: HP:0009726, renal neoplasm; HP:0031500, abdominal mass.
  • Flank or abdominal pain — variable, progressive as capsule or adjacent structures are involved. HPO: HP:0031605, flank pain; HP:0002027, abdominal pain.
  • Hematuria — intermittent gross or microscopic bleeding when collecting-system or vascular structures are invaded. HPO: HP:0000790, hematuria.
  • Constitutional effects: weight loss, fatigue, fever, anorexia, or anemia in advanced disease. Suggested HPO: HP:0001824, weight loss; HP:0012378, fatigue; HP:0001945, fever; HP:0001903, anemia.
  • Metastatic manifestations: cough/dyspnea from pulmonary metastases and bone pain/pathologic fracture from osseous spread. Among metastatic adult cases, lung involvement was reported in 68% and bone involvement in 41.2%. (uhlig2024epidemiologytreatmentand pages 3-5)
  • Laboratory abnormalities: anemia, hematuria, impaired renal function, or elevated inflammatory indices can occur, but none is sensitive or specific. There is no validated serum tumor marker.

Severity is highly variable but frequently substantial: median tumor diameter was approximately 10 cm, and almost half of registry patients had T3–T4 disease. Pain, cancer-related fatigue, loss of renal function after nephrectomy, systemic-therapy toxicity, fear of recurrence, and metastatic disability impair quality of life. No kidney-sarcoma-specific EQ-5D, SF-36, or PROMIS reference dataset was identified. (uhlig2024epidemiologytreatmentand pages 1-2, uhlig2024epidemiologytreatmentand pages 7-9)

4. Genetic and molecular information

Subtype / typical age Defining tumor alteration Useful IHC Clinical behavior Usual treatment framework
Adult renal leiomyosarcoma; typically older adults, median age about 62 y in national data Usually complex-karyotype smooth-muscle sarcoma; no single pathognomonic renal-specific fusion established in gathered evidence Smooth-muscle markers are typically used in practice; p16/p53 overexpression reported as potential prognostic indicators in review literature Most common adult renal sarcoma histotype; often presents as a large renal mass and can be locally advanced or metastatic; among renal sarcoma histotypes, outcomes were relatively more favorable than angiosarcoma in 2024 registry analysis (uhlig2024epidemiologytreatmentand pages 1-2, uhlig2024epidemiologytreatmentand pages 3-5, uhlig2024epidemiologytreatmentand pages 5-7, mohd2022etiologiesgrossappearance pages 9-10) Complete surgical resection/nephrectomy is the mainstay; systemic therapy considered for advanced disease, with histology-tailored soft-tissue sarcoma regimens rather than renal-cell-carcinoma-specific therapy (uhlig2024epidemiologytreatmentand pages 5-7, uhlig2024epidemiologytreatmentand pages 7-9, uhlig2024epidemiologytreatmentand pages 9-10)
Renal synovial sarcoma; usually adolescents/young-to-middle-aged adults SS18::SSX fusion (classically SS18-SSX1/2), causing BAF/chromatin-remodeling dysregulation; this is the defining lesion of synovial sarcoma generally (OpenTargets Search: kidney sarcoma) TLE1, cytokeratin/EMA, CD99 may support diagnosis; SS18-SSX fusion-specific testing or molecular confirmation is preferred; diffuse SS18-SSX antibody staining is useful in modern practice for synovial sarcoma generally (OpenTargets Search: kidney sarcoma) Rare primary renal spindle-cell sarcoma; can mimic other renal spindle tumors, so expert molecular pathology is important Surgery with negative margins when localized; for advanced disease, treatment is generally extrapolated from synovial/soft-tissue sarcoma practice, with chemotherapy in selected patients (uhlig2024epidemiologytreatmentand pages 7-9, uhlig2024epidemiologytreatmentand pages 9-10)
Renal Ewing sarcoma / PNET; mainly children, adolescents, and young adults EWSR1::FLI1 or related Ewing-family fusion; defining molecular event of Ewing sarcoma family tumors (bradford2020primaryrenalewing pages 7-7, bradford2020primaryrenalewing pages 5-7) CD99+, FLI1+, NKX2.2+ are useful supportive markers; molecular confirmation is required (bradford2020primaryrenalewing pages 5-7) Aggressive renal presentation with high metastatic burden at diagnosis; pooled analysis found metastases at diagnosis in about 53% and nodal disease more frequent than in skeletal Ewing sarcoma (bradford2020primaryrenalewing pages 7-7, bradford2020primaryrenalewing pages 5-7) Multimodal therapy: neoadjuvant/adjuvant VDC/IE-based chemotherapy, nephrectomy aiming for negative margins, and selective radiotherapy (bradford2020primaryrenalewing pages 7-7)
Pediatric clear cell sarcoma of kidney (CCSK); usually early childhood; distinct entity often confused with “kidney sarcoma” BCOR internal tandem duplication is characteristic in many cases; YWHAE::NUTM2 occurs in a subset; biologically distinct from adult primary renal sarcoma umbrella (OpenTargets Search: kidney sarcoma) BCOR immunoreactivity is commonly used in practice; differential diagnosis requires molecular correlation because BCOR expression can occur in other sarcomas (OpenTargets Search: kidney sarcoma) Pediatric malignant renal tumor distinct from adult renal sarcomas; included here because of naming confusion rather than because it is the same disease category Pediatric renal-tumor protocols using surgery plus multiagent chemotherapy, with radiotherapy in selected cases; not managed as adult renal sarcoma (OpenTargets Search: kidney sarcoma)
Primary renal angiosarcoma; usually adults No single defining recurrent renal-specific alteration established in gathered evidence; endothelial-lineage malignant vascular sarcoma Endothelial markers are typically used in practice (for example CD31/CD34/ERG in angiosarcoma workups) Very rare and aggressive; 2024 renal-sarcoma analysis found worse prognosis than leiomyosarcoma (HR 2.42) (uhlig2024epidemiologytreatmentand pages 5-7) Surgery when feasible; systemic therapy for advanced disease is extrapolated from angiosarcoma/STS practice; radiation used infrequently overall in renal sarcoma cohorts (uhlig2024epidemiologytreatmentand pages 5-7, uhlig2024epidemiologytreatmentand pages 7-9)
Malignant rhabdoid tumor of kidney; predominantly infants/young children, but adult renal rhabdoid tumors were captured in registry data Classically associated with SMARCB1/INI1 loss in malignant rhabdoid tumors generally; renal-sarcoma registry identified this as one of the more common histotypes INI1/SMARCB1 loss is the key diagnostic immunophenotypic finding in routine practice for rhabdoid tumors generally Highly aggressive; one of the more common histotypes in the adult registry compilation despite overall rarity of adult cases (uhlig2024epidemiologytreatmentand pages 1-2, uhlig2024epidemiologytreatmentand pages 7-9) Surgery is central when possible; multimodal pediatric or rhabdoid-tumor-directed systemic therapy is typically required, but renal-specific adult evidence is sparse (uhlig2024epidemiologytreatmentand pages 5-7, uhlig2024epidemiologytreatmentand pages 7-9)
Sclerosing epithelioid fibrosarcoma of kidney (SEF); very rare adults EWSR1::CREB3L1 fusion reported in renal SEF; molecularly distinctive fibroblastic sarcoma (baydar2015primarysclerosingepithelioid pages 12-12) MUC4, vimentin, BCL2 positive; negative for S100, CD34, desmin in reported renal cases (baydar2015primarysclerosingepithelioid pages 12-12) Exceptionally rare; at least one reported renal case had widespread metastases at diagnosis, indicating potentially aggressive behavior (baydar2015primarysclerosingepithelioid pages 12-12) Complete excision when feasible; no renal-SEF-specific systemic standard established in gathered evidence (baydar2015primarysclerosingepithelioid pages 12-12)

Table: This table summarizes the major histologic entities that present as primary renal sarcoma or are commonly confused with it, highlighting subtype-defining molecular alterations, practical diagnostic markers, behavior, and treatment logic. It is useful for distinguishing the heterogeneous adult renal sarcoma umbrella from specific fusion-defined and pediatric renal tumor entities.

Interpretation of variants

These rearrangements/ITDs are somatic structural oncogenic events, generally absent from population germline databases; therefore, gnomAD allele frequency and Mendelian carrier frequency are not meaningful. They should be reported under AMP/ASCO/CAP somatic-oncology conventions, not assigned germline ACMG pathogenicity without separate constitutional testing.

  • Synovial sarcoma: t(X;18) produces SS18::SSX1/SSX2, replacing native SS18 in the BAF/SWI–SNF chromatin-remodeling complex and reprogramming enhancer accessibility. Open Targets strongly associates SS18, SSX1, and SSX2 with synovial sarcoma. (OpenTargets Search: kidney sarcoma)
  • Ewing sarcoma: usually EWSR1::FLI1, an aberrant ETS transcription factor that rewires enhancer activity, cell-cycle programs, differentiation, and invasion. Renal disease shares the canonical molecular lesion but has disproportionately aggressive presentation. (bradford2020primaryrenalewing pages 7-7, bradford2020primaryrenalewing pages 5-7)
  • CCSK: most tumors contain a BCOR exon-15 internal tandem duplication; a smaller, usually mutually exclusive group carries YWHAE::NUTM2. NTRK3 transcription/protein overexpression is reported across BCOR-family tumors, including CCSK, but is not equivalent to an actionable NTRK fusion. (OpenTargets Search: kidney sarcoma)
  • SEF: reported renal tumors were MUC4-positive and carried EWSR1::CREB3L1. One of two patients had disseminated disease at diagnosis. (baydar2015primarysclerosingepithelioid pages 12-12)
  • LMS: usually has a complex genome rather than one defining fusion; disruption of TP53/RB1/PTEN-associated cell-cycle and survival control is biologically plausible across LMS. Renal-specific comprehensive genomic series remain scarce.

No validated kidney-sarcoma modifier genes, protective alleles, founder variants, germline mosaicism, anticipation, or carrier frequency are known. Constitutional testing is appropriate only when age, multiple tumors, family history, or pathology suggests a predisposition syndrome.

5. Environmental information

There is no reproducible renal-sarcoma-specific association with smoking, alcohol, diet, exercise, air pollution, pesticides, or occupational agents. Prior radiotherapy is a recognized general cause of radiation-induced STS after latency, but a primary renal sarcoma should be labeled radiation-associated only when accepted temporal and anatomic criteria are met. No bacterial, viral, fungal, or parasitic cause applies to the conventional disease. Prevention databases should therefore record most proposed exposures as unknown/not established, not negative causal facts.

6. Mechanism and pathophysiology

Causal chain

  1. Initiation: a renal mesenchymal/progenitor, smooth-muscle, vascular-endothelial, or poorly differentiated precursor acquires a subtype-defining fusion or complex tumor-suppressor damage.
  2. Upstream transcriptional/chromatin dysregulation: fusion proteins such as SS18::SSX and EWSR1::FLI1 alter chromatin occupancy and transcription; BCOR lesions disturb Polycomb-associated repression.
  3. Downstream processes: sustained proliferation, failed differentiation, apoptosis evasion, angiogenesis, extracellular-matrix remodeling, invasion, and metastatic dissemination.
  4. Tissue injury: expansile growth causes compression and ischemia; invasion produces hemorrhage, necrosis, collecting-system bleeding, and replacement of renal parenchyma.
  5. Clinical expression: mass, pain, hematuria, anemia, loss of renal function, and lung/bone/nodal metastases.

Suggested GO biological processes include GO:0007049 cell cycle, GO:0008283 cell population proliferation, GO:0006915 apoptotic process, GO:0001525 angiogenesis, GO:0030198 extracellular matrix organization, GO:0007155 cell adhesion, GO:0016477 cell migration, and GO:0006355 regulation of DNA-templated transcription. Relevant cell types include CL:0000192 smooth muscle cell for LMS, CL:0000115 endothelial cell for angiosarcoma, CL:0000057 fibroblast for fibroblastic sarcomas, and an incompletely resolved primitive mesenchymal progenitor for fusion-driven round-cell tumors.

Molecular profiling and advanced technologies

No TCGA-scale, kidney-sarcoma-specific single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic, or integrated multi-omics atlas was identified. Existing evidence comes mainly from bulk tumor sequencing, fusion assays, IHC, and histotype-level sarcoma datasets. This lack of renal-specific molecular profiling is a major research gap and precludes defining a universal metabolic or immune signature.

7. Anatomical structures affected

  • Primary organ: kidney — suggested UBERON:0002113.
  • Potential sites of origin: renal capsule, parenchymal interstitium, renal sinus, pelvis-adjacent soft tissue, and renal vascular smooth muscle/endothelium.
  • Local extension: perinephric fat, Gerota fascia, renal vein/inferior vena cava, adrenal gland, psoas, bowel, pancreas, spleen, liver, or abdominal wall depending on side and size.
  • Secondary organs: lung and bone predominate; regional lymph nodes are particularly important in renal Ewing sarcoma. Renal ESFT nodal disease occurred in approximately 24%, compared with 3.2% in skeletal ESFT. (bradford2020primaryrenalewing pages 5-7)
  • Laterality: generally unilateral; no consistent right/left preference is established.
  • Subcellular compartments: nucleus/chromatin for fusion-driven transcriptional mechanisms (GO:0005634 nucleus, GO:0000785 chromatin); cytoskeleton/contractile apparatus in LMS; endothelial junctions and extracellular matrix in angiosarcoma.

8. Temporal development

Adult LMS and angiosarcoma usually develop insidiously in middle-to-late adulthood; renal synovial and Ewing sarcomas affect younger patients; CCSK and rhabdoid tumor are chiefly pediatric. The course is progressive rather than episodic. Localized disease may enter treatment-induced remission after complete resection, but high-grade tumors can recur locally or hematogenously years later.

Renal Ewing sarcoma is often rapidly progressive: pooled evidence found 53.2% metastatic at diagnosis, substantially exceeding the general Ewing population. In the reported pediatric/young-adult institutional series, five of seven patients relapsed after initial remission. (bradford2020primaryrenalewing pages 7-7, bradford2020primaryrenalewing pages 5-7)

Staging should use the applicable AJCC soft-tissue sarcoma site/stage framework, supplemented by FNCLCC grade where valid for the histotype. CCSK, rhabdoid tumor, and Ewing sarcoma follow pediatric/diagnosis-specific staging and response systems rather than adult retroperitoneal STS rules.

9. Inheritance and population

The overall incidence was 0.53 cases per million persons annually during 2004–2016, stable over time (AAPC 0.7%; p=0.6). LMS alone occurred at 0.14/million and malignant rhabdoid tumor at 0.06/million. (uhlig2024epidemiologytreatmentand pages 1-2)

No conventional inheritance pattern, penetrance, anticipation, carrier state, founder effect, or consanguinity relationship applies to the umbrella diagnosis. Most defining alterations are acquired in the tumor. The national cohort showed marked sex variation by histotype rather than one universal sex ratio. No robust ethnicity-specific or geographic concentration is established; apparent differences are vulnerable to small numbers and registry ascertainment. (uhlig2024epidemiologytreatmentand pages 3-5)

10. Diagnostics

Recommended workflow

  1. Imaging: multiphasic contrast CT or MRI of the abdomen/pelvis to define renal origin, local invasion, vessel involvement, and resectability; CT chest for pulmonary staging. MRI is especially useful for venous thrombus and soft-tissue planes. PET/CT is selective, not a substitute for chest/abdominal staging.
  2. Multidisciplinary review: radiology, urologic/sarcoma surgery, medical and radiation oncology, and specialist sarcoma pathology before definitive treatment.
  3. Biopsy: image-guided coaxial core biopsy along a tract that can be removed or safely encompassed. Upfront surgery may be reasonable for a resectable renal mass when management would not change, but biopsy is particularly valuable for unresectable/metastatic disease or when neoadjuvant therapy is contemplated.
  4. Histology/IHC: determine spindle, round-cell, pleomorphic, vascular, or epithelioid pattern; assess mitoses, necrosis, grade, and margins. A practical panel may include pancytokeratin/EMA and PAX8 to exclude carcinoma; SMA/desmin/h-caldesmon for LMS; ERG/CD31 for angiosarcoma; S100/SOX10; myogenin/MyoD1; CD99/NKX2.2; TLE1 and SS18–SSX; BCOR; INI1; MDM2; STAT6; and MUC4 according to morphology.
  5. Molecular confirmation: targeted RNA sequencing is preferred for suspected fusion sarcoma; alternatives include break-apart FISH, RT-PCR, or fusion-specific IHC. DNA NGS is useful for complex-genome tumors and actionable alterations but can miss RNA-level fusions.

Differential diagnosis

The essential exclusions are sarcomatoid RCC, collecting-duct/urothelial carcinoma, Wilms tumor, CCSK, malignant rhabdoid tumor, angiomyolipoma/PEComa, solitary fibrous tumor, retroperitoneal liposarcoma secondarily involving kidney, metastasis, lymphoma, and benign leiomyoma. Renal sarcoma and retroperitoneal sarcoma can be difficult to distinguish anatomically; expert radiology and examination of the resection relationship to renal parenchyma/capsule are required. (uhlig2024epidemiologytreatmentand pages 9-10)

No blood/urine biomarker, liquid-biopsy assay, WES/WGS screen, CMA, karyotype, mitochondrial assay, or repeat-expansion test is recommended for routine asymptomatic screening. Germline panel/WES is reserved for clinical suspicion of inherited predisposition.

11. Outcome and prognosis

Across the 2024 adult cohort, median OS was 25 months, although outcomes differed greatly by histotype and stage. Angiosarcoma had worse survival than LMS (HR 2.42). Independently favorable factors included younger age, female sex, lower comorbidity, lower T stage, negative margins, no necrosis, no distant metastasis, and LMS histology. (uhlig2024epidemiologytreatmentand pages 1-2, uhlig2024epidemiologytreatmentand pages 5-7)

Positive margins occurred in 21.3% overall and 40.6% of T4 resections, emphasizing the importance of planned en-bloc surgery. Distant disease was present in approximately 29–32%. (uhlig2024epidemiologytreatmentand pages 3-5, uhlig2024epidemiologytreatmentand pages 5-7)

For renal Ewing sarcoma, localized survival was reported at approximately 55%, while metastatic and nodal disease predicted inferior OS. Pulmonary-only metastasis generally fares better than bone/bone-marrow disease, but renal-primary outcomes remain worse than conventional localized Ewing benchmarks. (bradford2020primaryrenalewing pages 7-7, bradford2020primaryrenalewing pages 5-7)

Functional morbidity includes nephrectomy-related reduction in renal reserve, chronic kidney disease risk, chemotherapy cardiotoxicity/myelosuppression, ifosfamide nephrotoxicity/Fanconi syndrome, radiation injury, chronic pain, and disability from metastatic disease. Kidney-specific quality-of-life and disability-adjusted-life-year estimates are unavailable.

12. Treatment and real-world implementation

Localized adult disease

Complete en-bloc resection with microscopically negative margins (R0) is the only established curative foundation—usually radical nephrectomy, occasionally organ-sparing resection for carefully selected small lesions. In the national cohort, 81.6% underwent resection and 69.3% underwent radical/total nephrectomy. Suggested NCIt terms: Radical Nephrectomy, Partial Nephrectomy, Surgical Resection, and Metastasectomy. (uhlig2024epidemiologytreatmentand pages 1-2, uhlig2024epidemiologytreatmentand pages 3-5)

Routine lymphadenectomy is not supported for all adult STS histotypes, although suspicious nodes should be removed and nodal evaluation is particularly relevant to renal Ewing sarcoma. Radiotherapy may be considered for close/positive margins, unresectable local disease, palliation, or selected radiosensitive histotypes, but renal-adjacent bowel/liver/spinal cord and the remaining kidney constrain dose.

Systemic therapy

Treatment should follow histotype-specific STS practice:

  • Adult LMS/undifferentiated or pleomorphic STS: doxorubicin, doxorubicin–ifosfamide when tumor shrinkage is critical, or gemcitabine–docetaxel; later options may include pazopanib, trabectedin, dacarbazine, or eribulin according to histology, prior therapy, jurisdiction, and patient fitness.
  • Renal synovial sarcoma: comparatively ifosfamide-sensitive; anthracycline/ifosfamide-based therapy is commonly used for high-risk or advanced disease.
  • Renal Ewing sarcoma: interval-compressed VDC/IE—vincristine/doxorubicin/cyclophosphamide alternating with ifosfamide/etoposide—plus nephrectomy/local control and completion chemotherapy. The review describes 8–12 weeks of preoperative chemotherapy followed by negative-margin surgery and selective postoperative radiation. Suggested NCIt terms include the individual agents, Combination Chemotherapy, External Beam Radiation Therapy, and Nephrectomy. (bradford2020primaryrenalewing pages 7-7)
  • CCSK/rhabdoid tumor: pediatric cooperative-group protocols combining nephrectomy, intensive multiagent chemotherapy, and stage/risk-directed radiotherapy; these should not be treated as adult LMS.
  • Angiosarcoma: taxane- or anthracycline-based therapy and selected antiangiogenic approaches are extrapolated from nonrenal angiosarcoma.

In real-world renal sarcoma, systemic therapy was used in only 16.1% of localized cases, 39.8% of T4 cases, and 54.6% of metastatic cases; 93.3% of systemic treatment was adjuvant and only 4.6% neoadjuvant. Primary-site radiotherapy was used in 5.2%. Registry associations suggested benefit from systemic treatment in LMS, angiosarcoma, and clear-cell sarcoma, but confounding by indication prevents causal interpretation. (uhlig2024epidemiologytreatmentand pages 5-7, uhlig2024epidemiologytreatmentand pages 7-9)

Targeted, immune, cellular, and experimental treatment

Broad DNA/RNA profiling is reasonable in advanced disease to identify rare actionable fusions or mutations. Open Targets links kidney sarcoma chiefly to chemotherapy targets such as TOP2A and tubulins, reflecting anthracycline and microtubule-directed regimens rather than kidney-specific dependencies. In synovial sarcoma, SS18/SSX are causal but not yet routine drug targets. (OpenTargets Search: kidney sarcoma)

Checkpoint inhibitors have no established kidney-sarcoma-wide role; efficacy is histotype-dependent and generally lower in fusion-driven, low-mutation-burden tumors. Do not extrapolate the marked checkpoint sensitivity of sarcomatoid RCC to true renal sarcoma.

Relevant basket or adjacent trials identified include NCT02795819 (AR-42 plus pazopanib; phase I, terminated after six participants), NCT03798106 (pazopanib plus durvalumab in metastatic STS; phase II, completed), and NCT06444880 (ubamatamab ± cemiplimab in MUC16-expressing SMARCB1-deficient malignancies; phase II, active-not-recruiting). These are not proof of efficacy specifically in primary renal sarcoma.

13. Prevention

  • Primary prevention: no disease-specific intervention or vaccine.
  • Secondary prevention: no population screening; rarity makes ultrasound, CT, urine, or molecular screening unjustified in average-risk asymptomatic people.
  • High-risk genetics: counseling and syndrome-specific surveillance only when a constitutional predisposition is clinically demonstrated; no kidney-sarcoma-specific carrier screening, prenatal test, or preimplantation-testing recommendation exists.
  • Tertiary prevention: expert surgery, preservation of contralateral renal function, avoidance of nephrotoxins, rehabilitation, thrombosis/pain/nutrition management, and structured surveillance to detect resectable recurrence.
  • Follow-up: chest and abdominal cross-sectional imaging should be individualized by grade, histotype, stage, and treatment; high-grade disease requires closer early follow-up because lung relapse is common.

14. Other species and natural disease

Naturally occurring primary renal LMS has been reported in domestic cats (NCBI Taxon 9685; Felis catus), but evidence consists primarily of isolated veterinary case reports. Similar renal spindle-cell morphology and smooth-muscle immunophenotype provide comparative-pathology interest, not a validated translational model. Breed predisposition and Vertebrate Breed Ontology associations are unknown. Sporadic renal sarcomas also occur in dogs, but robust incidence and molecular-concordance studies are lacking. There is no zoonotic or cross-species transmission.

15. Model organisms and experimental systems

No single model captures the 43-histotype renal-sarcoma umbrella. Models are subtype-specific:

  • human cell lines and 2-D/3-D cultures;
  • subcutaneous or renal-subcapsular xenografts in immunodeficient mice;
  • patient-derived xenografts/orthotopic xenografts;
  • fusion-driven Ewing or synovial sarcoma genetically engineered mouse models;
  • zebrafish embryo and chick chorioallantoic-membrane xenografts for rapid invasion and drug-response studies.

Renal-subcapsular xenografting supplies a vascular microenvironment and allows growth/metastasis studies, but implantation site does not prove renal cell of origin. Xenografts retain human tumor genetics but lack an intact human immune system; GEMMs model initiation and immune interactions but can underrepresent human genomic complexity and metastasis. Accordingly, these systems support mechanism and drug discovery at the histotype level, not validation of one universal kidney-sarcoma mechanism.

Evidence appraisal and research priorities

The 2024 SEER/NCDB analysis is the best contemporary population evidence, but it lacked treatment-regimen detail, mutation status, complete grade information, and robust radiotherapy numbers. Its treatment-survival associations are retrospective. The renal Ewing literature is larger than that for most subtypes but remains vulnerable to publication bias. (uhlig2024epidemiologytreatmentand pages 9-10, bradford2020primaryrenalewing pages 5-7)

Priority needs are prospective international registration with central pathology review; mandatory RNA-fusion and DNA profiling; histotype-stratified treatment data; renal-specific organoid/PDX models; single-cell and spatial profiling; circulating-tumor-DNA studies; patient-reported outcomes; and trials that enroll by molecular histotype rather than merely renal site.

Selected recent and authoritative sources

  1. Uhlig J, et al. “Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients.” Scientific Reports. Published May 2024. DOI/URL: https://doi.org/10.1038/s41598-024-60174-8. Abstract quotation: “Accounting for 0.25% of renal malignancies, renal sarcomas include 43 histiotypes with distinct epidemiology, clinical presentation, outcomes and sensitivity to systemic therapy.” (uhlig2024epidemiologytreatmentand pages 1-2)
  2. Bradford K, et al. “Primary Renal Ewing Sarcoma in Children and Young Adults.” Journal of Pediatric Hematology/Oncology. Published April 2020. DOI/URL: https://doi.org/10.1097/MPH.0000000000001804. Abstract quotation: “primary renal ESFT presentations seem to be more aggressive and have worse outcomes.” (bradford2020primaryrenalewing pages 7-7, bradford2020primaryrenalewing pages 5-7)
  3. Baydar DE, et al. “Primary sclerosing epithelioid fibrosarcoma of kidney…” Diagnostic Pathology. Published October 2015. DOI/URL: https://doi.org/10.1186/s13000-015-0420-z. The reported renal tumors showed MUC4 expression and EWSR1–CREB3L1 fusion. (baydar2015primarysclerosingepithelioid pages 12-12)
  4. Open Targets Platform, kidney sarcoma MONDO:0002930. Disease–target evidence includes chemotherapy-associated TOP2A/tubulin targets and subtype-defining SS18/SSX associations for synovial sarcoma: https://platform.opentargets.org/. (OpenTargets Search: kidney sarcoma)

References

  1. (uhlig2024epidemiologytreatmentand pages 1-2): Johannes Uhlig, Annemarie Uhlig, Hari Deshpande, Philipp Ströbel, Lutz Trojan, Joachim Lotz, Michael Hurwitz, Omeed Hafez, Peter Humphrey, Viktor Grünwald, and Hyun S. Kim. Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients. Scientific Reports, May 2024. URL: https://doi.org/10.1038/s41598-024-60174-8, doi:10.1038/s41598-024-60174-8. This article has 7 citations and is from a peer-reviewed journal.

  2. (uhlig2024epidemiologytreatmentand pages 5-7): Johannes Uhlig, Annemarie Uhlig, Hari Deshpande, Philipp Ströbel, Lutz Trojan, Joachim Lotz, Michael Hurwitz, Omeed Hafez, Peter Humphrey, Viktor Grünwald, and Hyun S. Kim. Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients. Scientific Reports, May 2024. URL: https://doi.org/10.1038/s41598-024-60174-8, doi:10.1038/s41598-024-60174-8. This article has 7 citations and is from a peer-reviewed journal.

  3. (uhlig2024epidemiologytreatmentand pages 9-10): Johannes Uhlig, Annemarie Uhlig, Hari Deshpande, Philipp Ströbel, Lutz Trojan, Joachim Lotz, Michael Hurwitz, Omeed Hafez, Peter Humphrey, Viktor Grünwald, and Hyun S. Kim. Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients. Scientific Reports, May 2024. URL: https://doi.org/10.1038/s41598-024-60174-8, doi:10.1038/s41598-024-60174-8. This article has 7 citations and is from a peer-reviewed journal.

  4. (uhlig2024epidemiologytreatmentand pages 7-9): Johannes Uhlig, Annemarie Uhlig, Hari Deshpande, Philipp Ströbel, Lutz Trojan, Joachim Lotz, Michael Hurwitz, Omeed Hafez, Peter Humphrey, Viktor Grünwald, and Hyun S. Kim. Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients. Scientific Reports, May 2024. URL: https://doi.org/10.1038/s41598-024-60174-8, doi:10.1038/s41598-024-60174-8. This article has 7 citations and is from a peer-reviewed journal.

  5. (OpenTargets Search: kidney sarcoma): Open Targets Query (kidney sarcoma, 50 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  6. (bradford2020primaryrenalewing pages 7-7): Kathryn Bradford, Alexander Nobori, Brittany Johnson, Wendy Allen-Rhoades, Bindi Naik-Mathuria, Eduard H. Panosyan, Moran Gotesman, Joseph Lasky, Jerry Cheng, Alan Ikeda, Jeffrey Goldstein, Arun Singh, and Noah Federman. Primary renal ewing sarcoma in children and young adults. Journal of Pediatric Hematology/Oncology, 42:474-481, Apr 2020. URL: https://doi.org/10.1097/mph.0000000000001804, doi:10.1097/mph.0000000000001804. This article has 24 citations.

  7. (baydar2015primarysclerosingepithelioid pages 12-12): Dilek Ertoy Baydar, Kemal Kosemehmetoglu, Oguz Aydin, Julia A. Bridge, Berrin Buyukeren, and Fazil Tuncay Aki. Primary sclerosing epithelioid fibrosarcoma of kidney with variant histomorphologic features: report of 2 cases and review of the literature. Diagnostic Pathology, Oct 2015. URL: https://doi.org/10.1186/s13000-015-0420-z, doi:10.1186/s13000-015-0420-z. This article has 35 citations and is from a peer-reviewed journal.

  8. (uhlig2024epidemiologytreatmentand pages 3-5): Johannes Uhlig, Annemarie Uhlig, Hari Deshpande, Philipp Ströbel, Lutz Trojan, Joachim Lotz, Michael Hurwitz, Omeed Hafez, Peter Humphrey, Viktor Grünwald, and Hyun S. Kim. Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients. Scientific Reports, May 2024. URL: https://doi.org/10.1038/s41598-024-60174-8, doi:10.1038/s41598-024-60174-8. This article has 7 citations and is from a peer-reviewed journal.

  9. (mohd2022etiologiesgrossappearance pages 9-10): Ahmed B Mohd, Reem A Ghannam, Omar B Mohd, Rama Elayan, Khaled Albakri, Nesreen Huneiti, Farah Daraghmeh, Eman Al-khatatbeh, and Mohammad Al-thnaibat. Etiologies, gross appearance, histopathological patterns, prognosis, and best treatments for subtypes of renal carcinoma: an educational review. Cureus, Dec 2022. URL: https://doi.org/10.7759/cureus.32338, doi:10.7759/cureus.32338. This article has 24 citations.

  10. (bradford2020primaryrenalewing pages 5-7): Kathryn Bradford, Alexander Nobori, Brittany Johnson, Wendy Allen-Rhoades, Bindi Naik-Mathuria, Eduard H. Panosyan, Moran Gotesman, Joseph Lasky, Jerry Cheng, Alan Ikeda, Jeffrey Goldstein, Arun Singh, and Noah Federman. Primary renal ewing sarcoma in children and young adults. Journal of Pediatric Hematology/Oncology, 42:474-481, Apr 2020. URL: https://doi.org/10.1097/mph.0000000000001804, doi:10.1097/mph.0000000000001804. This article has 24 citations.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 5
Resolved 5
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 5
On topic 3
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 26
Resolved 26
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 0
Terms whose name was checked 3
Terms named correctly 3
Terms named as a different term 0

Every term resolved, and every label the report gave matched.